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ABSTRACT
The Role of Obesity, Diabetes, and Hypertension in Cleft Lip
and Cleft Palate Birth Defects
by
Hebah A. Kutbi, Doctor of Philosophy
Utah State University, 2014

Major Professor: Dr. Ronald Munger
Department: Nutrition, Dietetics, and Food Sciences

Orofacial clefts (OFCs) are among the most common structural birth defects
and a public health problem. Several studies suggest that maternal obesity preexisting diabetes mellitus (DM), and the underlying metabolic abnormalities, may be
involved in the pathogenesis of cleft lip (CL) and cleft palate (CP) birth defects.
Although hypertension and gestational diabetes mellitus (GDM) have been associated
in a few studies with congenital birth defects, studies examining the risk associated
with OFCs are limited. The overall objective of this dissertation was to examine the
association between maternal obesity, DM, GDM, and hypertension and the risk of
OFCs in case-control studies.
Analyses of data from an international consortium revealed that maternal
obesity (pre-pregnancy BMI >30), compared to normal weight (18.5<BMI>25), was
associated with an increased risk of cleft palate with or without cleft lip (CP/L)
(adjusted odds ratio (aOR) =1.13 [95% confidence intervals (CI) 1.01-1.25]). We also
found a marginal association between maternal underweight and CP/L (1.0
[reference]; aOR=1.14 [0.97-1.34]. CL only was not associated with maternal
bodyweight. Interestingly, among college-graduates, there was no increased risk of
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CP, but mothers with less than a completed college education had an increased risk of
CP for underweight and obesity.
Investigation of the Utah OFC data provided evidence that maternal
GDM is significantly associated with isolated (aOR=2.63 [1.30-5.34]) and nonisolated clefts (aOR=2.66 [1.02-6.97]). Maternal hypertension is significantly
associated with non-isolated clefts (aOR=6.56 [2.18-19.77]). We found a further
elevated risk of OFCs among GDM mothers and those with hypertension who were
also obese.
The analyses of data from an international consortium revealed significant
associations between maternal diabetes and the risk of OFCs. The estimated relative
risk of DM for isolated OFCs was 1.33 [1.14-1.54] and was slightly higher for
multiple OFCs (aOR=1.86 [1.44-2.40]). Diabetic mothers with abnormal body-massindex had an increased risk for having inborn with OFCs.
Throughout the dissertation, we demonstrated the extent in which maternal
obesity, pre-existing DM, GDM, and maternal hypertension may increase the risk of
OFC birth defects. The results highlight the need for pre-conceptional program
planning for the prevention of OFCs with screening for abnormal glucose tolerance
and hypertension.
(157 pages)
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PUBLIC ABSTRACT

The Role of Obesity, Diabetes, and Hypertension in Cleft Lip and
Cleft Palate Birth Defects
Hebah Kutbi

Orofacial clefts (OFCs) are birth defects characterized by immediately
recognizable disruption of normal facial structure caused by abnormal facial
development during the first six to eight weeks of gestation, causing a cleft in the lip
or the palate. OFCs are among the most common structural birth defects and a public
health problem. Some studies have found that maternal obesity, diabetes,
hypertension, or the underlying metabolic abnormalities known as the metabolic
syndrome, might be associated with the risk of OFCs, though other studies have been
inconsistent. Data of mothers who have had children with OFCs were compared to
those of children without OFCs to assess the association between maternal obesity,
diabetes or gestational diabetes, or hypertension and the risk of OFCs.
Results of studies conducted in this dissertation indicated an increased risk of
OFCs when abnormal maternal weight is present. Both maternal obesity and
underweight were found to be associated with increased risk of having children with
orofacial clefts. This effect however was only present among mothers with lower
maternal education levels. Maternal diabetes mellitus and gestational diabetes
increased the risk for having a child with OFC birth defects, as well as maternal
hypertension. When maternal diabetes or hypertension was combined with obesity or
underweight, the risk of OFC increased compared to normal weight mothers.
With the increased prevalence of obesity, diabetes, and hypertension and the
association of these syndromes with OFCs, it is recommended that mothers planning
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to become pregnant to follow healthy habits, maintain healthy weight, and be
screened for possible diabetes or hypertension prior to conception and early in
pregnancy.

vii

ACKNOWLEDGMENTS
I would like to express my special appreciation and thanks to Dr. Ronald
Munger. You have been a tremendous adviser for me. Thank you for encouraging my
research and allowing me to accomplish my goals. Thanks to the National Institute of
Health (NIH) for funding my research, and to my committee members, Drs.
Christopher Corcoran, Heidi Wengreen, Korry Hintz, and Michael Lefevre, for their
support and serving as my committee members. I would also like to thank you for
being flexible and allowing me to defend in the summer, where it is the time to be
spent with your family.
A special thanks to my family. Words cannot express how grateful I am to my
parents for all the sacrifices they have made on my behalf. Thank you for teaching me
to love learning and value education. Your prayer was what sustained me that far and
gave me the strength to complete this dissertation work. Thanks to my sister, brothers,
aunts, and uncles, who stayed in contact with me while we were more than 7,507
miles apart. Thanks to my Saudi friends in Logan for their support and alleviating my
loneliness being apart from my family. Another very special thanks to my lovely
husband Wail, who supported me from the very beginning, back in my undergraduate
studies. Thank you for being so patient in staying apart for 5 years, in an effort of
helping me to accomplish my dream, the PhD.

Hebah Kutbi

viii

CONTENTS
ABSTRACT ..................................................................................................... iii
PUBLIC ABSTRACT .......................................................................................v
ACKNOWLEDGMENTS .............................................................................. vii
LIST OF TABLES .............................................................................................x
LIST OF FIGURES ........................................................................................ xii
CHAPTER
1. INTRODUCTION .........................................................................................1
Dissertation Hypotheses and Objectives ................................................4
Dissertation Structure.............................................................................4
References ..............................................................................................6
2. OBESITY, DIABETES, AND HYPERTENSION AND CLEFT LIP AND
CLEFT PALATE BIRTH DEFECTS: A REVIEW ..........................................9
Birth Defects ..........................................................................................9
Cleft Lip and Cleft Palate Birth Defects ..............................................11
Epidemiology of Cleft Lip and Cleft Palate by Gender ...........12
Epidemiology of Cleft Lip and Cleft Palate Birth Defects by
the Geographical Variation ......................................................13
Environmental Risk Factors for Orofacial Clefts ....................15
Maternal Vitamin and Mineral Nutrition .................................22
Maternal Obesity and Underweight .....................................................25
Maternal Obesity and Underweight and Cleft Lip and Cleft Palate
Birth Defects ........................................................................................28
Maternal Diabetes ................................................................................31
Diagnoses of Diabetes..............................................................31
Epidemiology of Diabetes........................................................33
Maternal Diabetes and Cleft Lip and Cleft Palate Birth Defects .........34
Animal Studies .........................................................................34
Human Studies .........................................................................35
Hypertension ........................................................................................39
Maternal Hypertension and Cleft Lip and Cleft Palate Birth Defects .40
Metabolic Syndrome ............................................................................41

ix
Metabolic Syndrome: The Underlying Causal Mechanism Linking
Maternal Obesity, Diabetes, and Hypertension to OFCs? ...................46
References ............................................................................................47
3. MATERNAL OBESITY AND UNDERWEIGHT AND THE RISK OF
OROFACIAL CLEFTS ...................................................................................69
Abstract ................................................................................................69
Introduction ..........................................................................................70
Methods................................................................................................71
Results ..................................................................................................75
Discussion ............................................................................................85
Conclusions ..........................................................................................91
References ............................................................................................92
4. THE ROLE OF GESTATIONAL DIABETES MELLITUS AND
HYPERTENSION ON THE RISK OF OROFACIAL CLEFTS IN UTAH ...96
Abstract ................................................................................................96
Introduction ..........................................................................................97
Materials and Methods .........................................................................99
Results ................................................................................................102
Discussion ..........................................................................................107
References ..........................................................................................110
5. THE ASSOCIATION BETWEEN MATERNAL DIABETES AND
OROFACIAL CLEFTS IN AN INTERNATIONAL CONSORTIUM OF
CASE-CONTROL STUDIES ........................................................................114
Abstract ..............................................................................................114
Introduction ........................................................................................115
Materials and Methods .......................................................................117
Results ................................................................................................120
Discussion ..........................................................................................129
References ..........................................................................................134
6. SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS .............138
Summary ............................................................................................138
Limitations and Future Directions .....................................................140
Conclusions ........................................................................................142
References ..........................................................................................143
CURRICULUM VITAE ................................................................................144

LIST OF TABLES
Table

Page

3-1. Number of Controls and Orofacial Cleft Cases by Cleft Type and Study Site ....74
3-2. Demographic Characteristics of Mothers of Children with OFC Cases and
Controls by Study Sites ........................................................................................77
3-3. Risk of Orofacial Clefts by Maternal Body Weight Categories and Cleft Types.78
3-4. Risk of Isolated Orofacial Clefts by Maternal Body Weight Categories by Cleft
Types ....................................................................................................................79
3-5. Risk of Orofacial Clefts by Maternal Education Level by Cleft Type .................81
3-6. Adjusted Odds Ratio (aORs) and 95% Confidence Intervals (CI) of Cleft Palate,
with or Without cleft lip, Isolated or With Multiple Birth Defects By Maternal
Body Mass Index (BMI) Group, Stratified by Two Levels of Maternal
Education. ............................................................................................................82
3-7. Adjusted Odds Ratios (aORs) and 95 Percent Confidence Intervals (CIs) of
Isolated and Multiple OFCs Combined by maternal Body Mass Index group by
cleft type and study site ........................................................................................83
4-1. Demographic Characteristics of Orofacial Cleft Cases and Controls; Utah Child
and Family Health Study ...................................................................................104
4-2. Risk of Orofacial Clefts by Maternal Gestational Diabetes Mellitus by Cleft
Types ..................................................................................................................105
4-3. Risk of Orofacial Clefts by Maternal Hypertension by Cleft Types ..................106
4-4. Risk of Orofacial Clefts by Maternal Gestational Diabetes Mellitus by Cleft
Types Stratified by Maternal Body-Mass-Index (BMI) Categories ..................106
4-5. Risk of Orofacial Clefts by Maternal Hypertension by Cleft Types Stratified by
Maternal Body Weight Categories .....................................................................107
5-1. Number of Controls and Orofacial Cleft Cases by Cleft Type and Study Site ..121
5-2. Number of Orofacial Cleft Cases by Cleft Type; International Consortium of
Orofacial Cleft Case-Control Study ...................................................................121
5-3. Demographic Characteristics of Mothers of Children with Orofacial Cleft Cases
and Controls by Study Sites ...............................................................................123
5-4. Adjusted Odds Ratios (aORs) and 95 Percent Confidence Intervals (CIs) of
Orofacial Cleft Types and Subtypes by Maternal DM ......................................124

xi
5-5. Adjusted Odds Ratios (aORs) and 95 Percent Confidence Intervals (CIs) of
Orofacial Cleft Types by Maternal Diabetes Stratified by Maternal Body Weight
Categories ..........................................................................................................125
5-6. Adjusted Odds Ratios (aORs) and 95 Percent Confidence Intervals (CIs) of
Orofacial Cleft Types and Subtypes by Maternal Diabetes Stratified by Maternal
Body Weight Categories ....................................................................................127
5-7. Adjusted Odds Ratios (aORs) and 95 Percent Confidence Intervals (CIs) of
Orofacial Cleft Types and Subtypes by Maternal Diabetes Stratified by Maternal
Multivitamin (MVI) Use ....................................................................................128

xii
LIST OF FIGURES
Figure

Page

2-1. Pathways to Type-2 Diabetes Implicated by Identified Common Variant
Associations ........................................................................................................68
4-1. Summary of Putative Pathophysiologic Mechanisms in the Development of
Hypertension in Diabetes Mellitus. RAAS_Renin- Angiotensin-Aldosterone
System; SNS_Sympathetic Nervous System; VSMC_Vascular Smooth Muscle
Cell. ....................................................................................................................100

1
CHAPTER 1
INTRODUCTION
Each year an estimated 150,000 babies are born with birth defects in the
United States 1. According to a 1998 report of the National Center for Health
Statistics, birth defects cause one in five infant deaths, making them the leading cause
of infant mortality 1. The National Vital Statistics Report indicated that in 2010, infant
mortality rate due to congenital malformations was 127.7 per 100,000 live births,
accounting for 20.8% (n=5,107) of total infant deaths 2. Clefts of the lip and palate,
collectively termed orofacial clefts (OFCs), are among the most common structural
birth defects and are therefore a public health problem 3, 4. Between 1998 and 2001,
the Centers for Disease Control and Prevention (CDC) reported that 6,800 infants in
the United States were affected by OFCs annually 5. In 2010, an estimated 4,437 live
births per year had cleft lip or cleft palate 6. Several studies suggest that maternal
obesity, diabetes, or the underlying metabolic abnormalities known as Metabolic
Syndrome, may be involved in the pathogenesis of cleft lip and cleft palate 7-9. Yet,
further studies are needed for a more complete understanding of the etiology of this
disorder 10.
Obesity is defined as having a body-mass-index (BMI; weight in kg/height in
M2) of ≥30.0. Among adults, age-adjusted prevalence of obesity in 2007-2008 was
33.8%, with an overall 32.2% among men and 35.5% among women 11. However, it
was expected that by 2015, 41% of adults in the United States would be obese 12.
Increased adiposity is associated with an increased incidence of a number of
conditions, including diabetes mellitus (DM) 13 and hypertension 14. An increased risk
for DM begins to rise at a BMI of >30 13, whereas BMI above the normal range is
associated with a number of adverse reproductive health outcomes, including
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gestational diabetes mellitus (GDM) 15, pregnancy induced hypertension 16, and birth
defects 17.
Maternal DM before pregnancy (pre-gestational diabetes) has been associated
with congenital malformations, including OFCs, in the offspring. Poor glycemic
control in very early pregnancy may increase the malformations rate 18. However, prepregnancy care of mothers with existing diabetes may reduce the malformation risk
19

. There is less evidence on the teratogenic risk of GDM, although this disorder has

been suggested to be a human teratogenic factor 20. In 1985, congenital malformations
represented the largest single cause of mortality in infants of diabetic mothers 21.
Schaeffer et al. studied 3743 pregnancies diagnosed with GDM and found an
association between maternal blood glucose levels and the risk for major–but not
minor–congenital malformations in the offspring. Women with GDM were identified
in a screening program while birth defects were identified by intense pediatric
examinations at the time of discharge from the delivery unit 22.
Metabolic syndrome is a cluster of metabolic and physical characteristics that
raise the risk of developing heart disease, diabetes, and other diseases. These include
insulin resistance, hypertension, obesity, central body fat deposition, low HDL
cholesterol, and hypertriglyceridemia 23. In 2009, approximately 34% of adults met
the criteria for metabolic syndrome and its prevalence increases with age and BMI 24.
Hypertension, which complicates approximately 10% of all pregnancies,
remains a major cause of morbidity and mortality for both mother and fetus 25. Blood
pressure normally decreases early in pregnancy, and by the mid-trimester, diastolic
levels are often 10 mmHg lower than postpartum measurements. Pressures then
increase gradually, approaching pre-pregnant levels near term, and some have even
recorded transient rises in the immediate puerperium 26. Because cardiac output is
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also elevated, the decrease in blood pressure is primarily related to a marked decrease
in peripheral vascular resistance 25. Infants born to women who have hypertension
early in pregnancy have an increased risk of birth defects. In 2011, researchers at the
Kaiser Foundation Research Institute in California collected health information on
465,000 mother-infant pairs in the Kaiser Permanente Northern California health care
system and compared the risk of birth defects in infants born to mothers with
hypertension using antihypertensive drugs to that of infants born to mothers with
hypertension but not taking any antihypertensive drugs. Results indicated an
increased risk of major non-chromosomal congenital malformations in all mothers
with hypertension and the risk remained elevated even with the use of hypertensive
drugs during pregnancy 27.
Maternal diabetes, or the underlying metabolic abnormalities known as the
metabolic syndrome, was hypothesized to be involved in the pathogenesis of cleft lip
and cleft palate, while it was debated whether this is true also at maternal GDM. With
the rising rates of excess weight among pregnant women, even a modest effect of
maternal obesity may result in an increased population burden of OFC. Maternal
weight gain increases the risk for DM and hypertension. Although hypertension has
been associated in a few studies with congenital birth defects, studies examining the
risk associated with OFC are limited. Given the aforementioned information, this
dissertation is a step towards a comprehensive analyses of the effect of maternal
obesity, diabetes, GDM, and hypertension on the risk of OFC birth defects. Further
analyses were performed to describe possible potential confounders that may interact
with these risk factors. The work outlined in chapters one through six can be useful in
determining the associations between maternal obesity, diabetes, GDM, and
hypertension on the risk of OFC birth defects.
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Dissertation Hypotheses and Objectives
The overall objective of this dissertation was to examine the associations between
maternal obesity, diabetes, and hypertension and the risk of orofacial clefts. The
specific objectives and hypotheses of this dissertation are:
1. To determine whether maternal obesity is associated with the risk of cleft lip and
cleft palate. Maternal obesity is hypothesized to cause cleft lip and cleft palate via
metabolic abnormalities that affect fetal development. This hypothesis was
examined in analyses of data from a large international consortium of case-control
studies from Utah, Iowa, Norway, Denmark, and the U.S. National Birth Defects
Prevention Study.
2. To investigate whether maternal gestational diabetes and hypertension are
associated with risk of cleft lip and cleft palate. These two factors are
hypothesized to cause cleft lip and cleft palate via metabolic abnormalities that
affect fetal development. This set of related hypotheses was examined in analyses
of data from the Utah case-control cleft study.
3. To examine the association between maternal diabetes and the risk of cleft lip and
cleft palate. This hypothesis was examined in analyses of data from the
international consortium of case-control studies from Utah, Iowa, Norway,
Denmark, and the U.S. National Birth Defects Prevention Study.
Dissertation Structure
This dissertation is divided into six chapters.
Chapter 1 provides an introduction to the research along with outlines
covering study objectives and hypotheses.
Chapter 2 is titled “Obesity, Diabetes, and Hypertension and Cleft Lip and
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Cleft Palate Birth Defects: A Review.” This chapter provides literature review of each
of these three modifiers and evidence that they are related to the risk of orofacial
clefts.
Chapter 3 is titled “Maternal Obesity and Underweight and the Risk of
Orofacial Clefts.” Chapter 3 undertakes analyses of data from an international
consortium, including case-control studies from the U.S and Norway, to test whether
an association between maternal obesity and underweight and the risk of OFCs exist
after adjusting for potential confounders. The demographic characteristics for each
study site were explored. The risk of maternal body weight groups on OFC subtypes
(cleft lip only (CLO), cleft lip with or without cleft palate (CL/P), and cleft palate
with or without cleft lip (CP/L)) was tested among each study site. The association
between maternal education levels and the risk of each OFC subtype (CLO, CLP,
cleft palate only (CPO), CP/L, and all cleft subtypes) was also tested. Given the
known association between maternal education level and risk of orofacial clefts, the
risk of maternal body weight groups stratified by maternal education levels was
examined.
Chapter 4 is titled “The Role of Gestational Diabetes Mellitus and
Hypertension on the Risk of Orofacial Clefts in Utah.” This chapter describes the
main characteristics of the Utah population sample and examines the independent
effect of maternal GDM and hypertension on the risk of cleft. Given that maternal
obesity is a risk factor for OFC, the effect of maternal GDM and hypertension is
assessed after stratifying data for maternal weight categories.
Chapter 5 is titled “The Association Between Maternal Diabetes and
Orofacial Clefts in an International Consortium of Case-Control Studies.” This
chapter examines the association between maternal diabetes and each type of OFC
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(isolated, multiple, and isolated and multiple clefts combined), and subtype (CLO,
CL/P, CPO, and all clefts) using data from an international consortium that includes
case-control studies from the U.S., Norway, and Denmark. The risk of maternal
diabetes was also tested within each maternal body weight category and obesity
levels.
Chapter 6 wraps up with a discussion on the findings and provides
conclusions and recommendation for further research directions and for practitioners.
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CHAPTER 2
OBESITY, DIABETES, AND HYPERTENSION AND CLEFT LIP
AND CLEFT PALATE BIRTH DEFECTS: A REVIEW
Birth Defects
Birth defects remain an important public health issue and the leading cause of
infant mortality and disabilities in the United States. The National Vital Statistics
Report indicated that in 2010, infant mortality rate due to congenital malformations
was 127.7 per 100,000 live births, accounting for 20.8% (n=5,107) of total infant
deaths 1. Children who survive and live with birth defects are faced with an increased
risk of developing life-long physical, cognitive, and social challenges concerning
which medical intervention and other supportive services have little impact 2. Parental
consanguineous marriages, advanced maternal age, maternal smoking, poverty, poor
nutrition, or alcohol and drug use are some of the risk factors that have been reported
to cause birth defects 3. The National Birth Defects Prevention Network (NBDPN)
provided an update of the national estimates of 21 selected birth defects.
Chromosomal anomalies were the most common birth defects, with a prevalence of
17.48 per 10,000 live births and accounting for 14.47 for Down syndrome, followed
by orofacial defects, cardiovascular, musculoskeletal, gastrointestinal, and central
nervous system defects, with prevalences of 16.98, 14.73, 14.13, 6.85, and 6.38 per
10,000 live births, respectively 4.
The Metropolitan Atlanta Congenital Defects Program (MACDP), a
population-based, active birth defects surveillance system operating in the five central
counties of metropolitan Atlanta, examined the prevalence of birth defects among
racial and ethnic subpopulations. Compared to births of non-Hispanic white women,
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births to non-Hispanic black women had a significantly higher prevalence of five
birth defects and a lower prevalence of 10 birth defects, while births to Hispanic
women had a higher prevalence of four birth defects and a lower prevalence of six
birth defects. However, the reasons for racial and ethnic variations in the prevalence
of birth defects are not well understood 5. Disparities in the prevalence of birth defects
may result from different underlying etiologies 5. Some birth defects are inherited,
while others are a product of harmful environmental factors or multifactorial,
resulting from a complex interaction of genetic and environmental influences.
Nevertheless, in about 50% of all birth defect cases, the causes remain unknown 6, 7.
Many birth defects occur due to abnormalities of the genetic material before
the conception 7. For instance, the chromosomal abnormalities, which are changes in
the number or structure of chromosomes and result in a gain or loss of genetic
material, account for approximately 6.0% of birth defects in industrialized countries 8.
Down syndrome, caused by an extra chromosome 21 (trisomy 21), is the most
common chromosomal abnormality 7; single gene defects that are caused by
alterations in gene structure (mutations) result in abnormal cell functioning and
accounts for 7.5% of birth defects; and multifactorial disorders, alternately called
congenital malformations, caused by the interaction of genes and the environment
compose 20-30% of all causes of birth defects. However, birth defects originating
after conception are largely non-genetic in origin. Intrauterine environmental factors,
such as congenital infections, maternal illness and altered maternal metabolism as
well as recreational and therapeutic drugs may cause the birth defects through the
process of interfering with the normal growth and development of the embryo and
deforming the fetus 7. Those birth defects compose 5-10% of the causes. Examples of
these three categories include rubella and toxoplasmosis, maternal insulin-dependent
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diabetes mellitus and iodine deficiency, and alcohol and antiepileptic drugs,
respectively. Unknown causes lead to 50% of the birth defects 7.
Birth defects are multifactorial occurring due to a combination of genes that
place the fetus at risk in the presence of specific environmental factors. A few
examples are congenital heart disease, neural tube defects, and OFCs. Multifactorial
inheritance can also be the cause of the many common systemic diseases with a
genetic predisposition presenting later in life. Examples are hypertension, diabetes,
stroke, mental disorders, and cancer 9.
Cleft Lip and Cleft Palate Birth Defects
Orofacial clefts (OFCs) are congenital malformations characterized by
immediately recognizable disruption of normal facial structure caused by abnormal
facial development during the first six to eight weeks of gestation, causing a cleft—a
gap. A cleft lip (CL) is a physical split or separation of one or both sides of the upper
lip and appears as a narrow opening in the skin of the upper lip. This rupture often
extends beyond the base of the nose and includes the alveolus, the bony structure of
the maxilla containing the gums and dentition. A cleft palate (CP) is a split or gap in
the palate, the roof of the mouth. A cleft palate can involve the hard palate (the bony
front portion of the roof of the mouth), and/or the soft palate (the soft back portion of
the roof of the mouth) 10.
It is important to distinguish between non-syndromic (isolated) and syndromic
CL/P in order to determine management and recurrence risk for patients and families
11

. Non-syndromic OFCs, are those that occur with no other major anomaly or one or

two minor anomalies 12 with an average prevalence of about 1/700 live births 13.
Major anomalies usually include those of functional significance requiring some
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degree of medical intervention. Minor anomalies, however, are those of minimal or
no functional significance 14. CL can occur on one or both sides of the mouth.
Because the lip and the palate develop separately, it is possible to have a CLO, a
CPO, or both together 15. Thus, it is reasonable to limit the definition of nonsyndromic OFCs to those associated with no additional malformations and one or two
minor anomalies. Affected individuals may have CL and CP (CLP), CP only (CPO),
or CL only (CLO) 15.
There appears to be a greater chance of clefting in a newborn if a sibling,
parent, or relative has had the defect. OFCs may cause complications in feeding,
dental problems, and speech, hearing, and social integration. However, OFCs can be
corrected to varying degrees by surgery, dental care, speech psychotherapy and
psychosocial intervention 16.
Epidemiology of Cleft Lip and Cleft Palate by Gender
Orofacial clefting is the most common craniofacial anomaly. Therefore, it is
important to analyze the distribution of this defect and describe its characteristics 17.
Using data from three registries of congenital anomalies based on a total of more than
5 million births, some epidemiological characteristics were studied for 8,315 infants
mainly with non-chromosomal CL/P. Robert et al. have observed a higher distribution
of CL/P among males than females, while gender ratio was lower when multiple
OFCs existed. The distribution of Pierre Robin type CP, which is a posterior Ushaped CP, was similar among males and females, while other types of CP had the
usual excess of females 18. Similarly, Mossey et al. have reported a higher frequency
of CL/P among males than females, while isolated CP was more commonly observed
among females 19. Gender ratio varied with severity of the cleft 19, presence of
additional malformations, number of affected siblings in a family, ethnic origin, and
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possibly paternal age 20. For instance, the gender ratio for CL/P in white populations
was about 2:1 (male: female). The male predominance in CL/P became more apparent
with increasing severity of cleft and less apparent when more than one sibling is
affected in the family 21, 22. By contrast, the male excess in CL/P is smaller when the
infant has malformations of other systems 20
Epidemiology of Cleft Lip and Cleft Palate Birth Defects by the Geographical
Variation
The birth frequency of CLO, CLP, and CPO is not known in some parts of the
world. Comparability of data related to the prevalence of OFCs among regions can be
affected considerably by the differences in sample source (hospital vs population),
duration, method of ascertainment, inclusion criteria, and sampling fluctuation 11.
The United States
Data from the California registry in the period 1983-1992 was used to estimate
the prevalence of CL/P among Native Americans. The prevalence of CL/P was
reported to be as high as 1.99 per 1000 births 23. The National Birth Defects
Prevention Network (NBDPN) examined the prevalence of OFCs by U.S. state. The
highest reported was for New Mexico in the period 1995-1996, with a prevalence of
1.73 per 1000 live births and the stillbirths combined. In Wisconsin 1989-1995, the
prevalence was 1.56 per 1000 live births and stillbirths combined. The lowest
recorded prevalence rate for CL/P was 0.59 per 1000 live births in Alaska, for 1996
only, and Illinois, for the period 1989-1996 11.
Latin America
The Latin American Collaborative Studies of Congenital Malformations
reported the prevalence of CL/P across Central and South America. The highest CL/P
prevalence recorded was for Bolivia (2.28 per 1000), followed by Argentina (1.16 per
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1000) and Chile (1.13 per 1000). These are geographically in the southern parts of
South America and are generally less developed than the U.S. and Canada 11. At the
lowest end of the scale was the geographically different population in Central
America and the Caribbean, reporting a prevalence of 0.42/1000, followed by
Venezuela (0.77 per 1000) 24.
Europe
The highest prevalence of CL/P from all European countries was 1.46 25.
Overall, the highest frequencies of CL/P were found in Norway, Denmark, Sweden,
Iceland, and the northern Netherlands, while the lowest levels were in Southern
Europe 11. In 2013, an epidemiological study conducted in Australia reported the
prevalence of OFCs among the Australian populace. The birth prevalence of CL/P
reported was 12.05 per 10,000 births (1 in 833 births). For CP, the prevalence was
10.12 per 10,000 births or 1 in 990 births. CL/P rates were significantly higher in
males than females; while for CP, the prevalence rate in females was significantly
higher than for males. Compared with non-Aboriginal Australians, birth prevalence
rates for Aboriginal Australians were 1.89 times higher for CL/P and 1.30 times
higher for CP. Birth prevalence of all forms of OFC did not differ by geographic
location or by socioeconomic status. From 1980 to 2009, there was no significant
change in annual rates for CL/P but rates for CP increased by an average of 1.97% per
year 26.
The Middle East
In the Middle East, the highest record of CL/P was 1.89 per 1000 live births in
a Saudi Arabian Hospital-based 27, followed by a reported non-syndromic prevalence
of OFCs in Kuwait ) in the period 1985-1987 (1.06 per 1000 live births28. In Turkey,
studies of OFCs are limited. However, it has been reported that 194 cases were
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identified with an age range of 1 to 65 years. Among the cases, 127 subjects (65.5%)
had isolated CP, including 63 females and 64 males; 42 (21.6%) subjects had CL,
including 17 females and 25 males; and 25 subjects (12.9%) had CLP, including 12
females and 13 males 29.
The Far East
The highest prevalence rate of OFCs in the Far East was reported from a
hospital-based Japanese data between 1948-1954, revealing a prevalence of 2.13 per
1000 live births 30. In the Philippines, a prevalence of 1.94 per 1000 live births was
reported for OFCs in a 7-year survey of hospital records in the period 1989-1996 31,
while in Taiwan, the prevalence of OFCs between 2002-2009 was 0.1% for CL/P and
0.04% for CP 32.
Environmental Risk Factors for Orofacial Clefts
Although the literature on OFCs is extensive, the exact etiology and the
unique risk factors remain unknown 11. Several studies suggested a multifactorial
etiology for OFC, with both genetic predisposition and environmental influence
playing a role 11. A meta-analysis investigated the potential maternal factors
associated with OFCs in the offspring. Data suggested that maternal socioeconomic
status, smoking, alcohol consumption, medications, caffeine, and lead exposure are
the most environmental risk factors associated with OFCs 33, 34, while folic acid intake
by the mother was found to reduce the risk of CL/P in offspring in several studies 33,
34

. In a Case-Control Study of non-syndromic OFCs in Maryland conducted to

examine both environmental and genetic risk factors for OFCs, and to test for possible
interactions, researchers could not find a statistically significant association with any
of the following: maternal smoking, vitamin use, urinary tract infection, or
recreational drug use. This could be explained by the small sample size in the study
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(n=171) 35.
Socioeconomic status (SES)
Several studies in the United States and other countries revealed possible
associations between parental socioeconomic status and the risks for birth defects,
including OFCs, though findings were inconsistent 36-39. For instance, a case-control
study conducted in France between 1985 and 1989 reported an increased risk for
OFCs among mothers with low SES measured by household income 40. The National
Birth Defects Prevention Study (NBDPS), an ongoing case-control study of about 30
different birth defects, started in 1997, examined individual and household SES in
relation to phenotypes of selected birth defects, including OFCs, based on 2,551
normal-formed live born controls and 1,841 cases delivered in 1997–2000. The
individual SES was measured by parental education, occupation, and household
income. Household SES index was defined by combining all individual SES
measures. Elevated risk of CPO in the offspring of fathers with lower education levels
and maternal operator/laborer occupation was observed 41. Mossey and colleagues
(2003) conducted a population-based case-control study in Scotland to investigate the
association between SES according to household income and OFCs. Results revealed
a strong association between OFC and SES, with a stronger pattern for CL/P than for
CPO 42. In a case-control study conducted in Philippines and included two separate
sites, maternal lower education level was significantly associated with an increased
risk of OFCs in Negros Occidental but not in Davao sample 43
In contrast, a population-based case-control study consisted of 696 case
mothers and 734 control mothers found no significant effect of SES on increasing the
risk for OFCs 39. Another population-based Hungarian case-control study included
1,374 cases with CL/P, 601 with posterior CP, and 38,151 controls and found no
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difference in SES status, measured by maternal employment, between mothers of
these two types of OFC cases and controls 44. In Sweden, Kallen reported no
association between low maternal education levels and the risk of OFCs 45. Different
measures of SES and different prevalences of birth defects across geographic
populations may have contributed to the inconsistent findings to some extent.
Smoking
Several studies investigating the association between maternal smoking and
the risk of OFCs have found positive associations with dosage effects 46-49, while
others had conflicting results 50-53. Population and sampling variations in addition to
the variation in inherited pharmacogenetic susceptibilities may contribute to the
disparities in cigarette smoking effects 54. For example, a meta-analysis that included
data from 24 case-control and cohort studies found a statistically significant
association between CL/P and maternal smoking. It was suggested that smoking
during pregnancy would increase the risk of having a child with CL/P and CP by 30%
and 20%, respectively 55. However, this association was significant for non-Hispanic
Whites, but not for non-Hispanic Blacks and Hispanics 56. Maternal passive smoking
has been also associated with increased risk of CL/P. A study conducted in Tehran,
Iran found a positive association between the environmental tobacco smoke exposure
and OFCs 57. Similarly, based on a study included 88 infants with CL/P and 651
infants without any major external birth defects, the odds ratio for CL/P associated
with maternal passive smoking was 1.8. After the adjustment for maternal occupation,
periconceptional flu or fever, and infant gender, the risk increased to 2.0.
Since the mid-1990s a number of epidemiological studies have investigated
interactions between various genes (transforming growth factor alpha (TGFa),
transforming growth factor beta-3 (TGFb3), retinoic acid receptor alpha (RARA),
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msh homeobox-1 (MSX1), cytochrome P (CYP), glutathione S-transferase (GST) and
epoxide hydrolase-1 (EPHX1)) 58 and markers in the glutathione s-transferase-1
(GSTT1) or nitric oxide synthase-3 (NOS3) gene 54, 59-61 and smoking by women
during pregnancy in relation to the development of CL/P in their offspring 58. Casetriads have suggested an association between a NAT2 haplotype and isolated CL but
with little evidence of interaction with smoking, but the other genes related to
detoxification of compounds of cigarette smoke (NAT2, CYP1A1, GSTP1, GSTT1,
and GSTM1) were not confirmed 62. Smoking has also been recently associated with a
joint risk with variants in IRF6, while the same study reported interactions between
multivitamins (MVIs) and IRF6 variants 63. These findings have been inconsistent,
suggesting that any interaction would probably explain only a small proportion of
OFCs. Such studies are still preliminary 55.
Alcohol consumption
Several studies have shown an association between prenatal alcohol exposure
and OFCs 64, 65, but the evidence has been more inconsistent 66. Studies also suggest
that ‘binge’ drinking patterns increase the risk of OFCs 67, which is supported by
associations with variation in the ADH1C alcohol dehydrogenase gene. However,
these links to alcohol consumption remain to be confirmed 68.
Maternal alcohol consumption was also examined in some studies in relation
to OFC in the offspring. For example, Werler et al. explored the association between
maternal alcohol use and the risk of birth defects in the offspring. Three measures of
alcohol exposures were used: (1) maximum number of drinks in any day (maximum
intensity), (2) average daily frequency, and (3) average intensity of drinking per day.
The only statistically significant increased risk was observed among CL/P cases in the
highest intake category, five or more drinks per day (odds ratio (OR)=3.0 [95%
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confidence intervals (CI) 1.1-8.5]) 69.
In a population-based case-control study conducted in Iowa between 1987 and
1991, cases were obtained from the Iowa Birth Defects Registry. Alcohol use was
categorized as 1-3, 4-10, or >10 drinks per month within the three months prior to
conception. CL/P risk was significantly associated with increasing alcohol exposure
64

. Another population-based case-control study of California births from 1987 to

1989, investigated the association between maternal alcohol use and the risk of OFCs.
Data on alcohol use was categorized as never, 1-3 during the four months critical
window period, 1-3 per month, 1-4 per week, or daily. The only significant
associations were found among mothers reporting five or more drinks per drinking
occasion, with ORs of 3.4 [95% CI 1.1-9.7] for isolated CL/P, 4.6 [95% CI 1.2-18.8]
for multiple CL/P, and 6.9 [95% CI 1.9-28.6] for syndromic OFCs 70. Romitti and
colleagues (1999) conducted a study in Iowa and found a significant increased risk for
CL/P among mothers reporting >4 drinks per month during the periconceptional
period 71. Yet, in a multicenter case-control study in four European countries where
alcohol use was defined as <70grams or >70 grams per week found a statistical
significant increased risk only for isolated and non-isolated CP. This finding was
inconsistent with the studies listed above, which showed no significant association
between maternal alcohol use and CP 65.
Medications
Inconsistent associations have been found when looking at OFCs and
anticonvulsant seizure medications, corticosteroids, or benzodiazepines, the antidepressant drugs 72-75. Epileptic women are at increased risk of having offspring with
OFCs 76-79. It was unclear whether the epilepsy or the drug therapy used to treat the
epilepsy that account for the increased clefting in epileptic women 11. Several studies
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reported the increased risk of congenital malformations, including OFCs, with the
anticonvulsant use to treat the epilepsy 78, 80-82. Smith has reported that more than 80%
of pregnant women exposed to trimethadion in utero as the only anticonvulsant
medication during pregnancy have either been spontaneously aborted or malformed at
birth. The most frequent major malformations reported were CL/P and cardiac defects
83

. Using data from a population-based case-control study, maternal epilepsy and

anticonvulsant drug therapy were both associated with increased risk of nonsyndromic CLP, but not with CPO 84.
Hashmi et al. used data from the NBDPS to evaluate the association of
maternal report of febrile illnesses in early pregnancy and the risk of OFCs. Mothers
reporting febrile illness during pregnancy were stratified by fever grade and
antipyretic use. The dataset included 5821 controls, 1567 cases of CL/P and 835 cases
of CPO. A modestly increased risk was observed for isolated CL/P. Stratification by
fever grade (body temperature <101.58 or 101.58F) did not yield significant
differences in risk. Risk estimates were higher among women who reported a fever
but did not take antipyretics to control their fever, particularly for non-isolated
compared with isolated OFCs. The authors suggested that adequate control of fever
may diminish the deleterious effects of fever in cases of OFC 85.
Corticosteroids are mainly used to treat asthma, lupus, and rheumatoid
disorders. Several studies reported a significant association between maternal use of
the corticosteroids during the first trimester of pregnancy and the risk of having
offspring with CL/P 74, 86, 87. It was theorized that the steroids act directly on the fetus,
resulting in the loss of amniotic fluids 88. It was also suggested that receptors of
glucocorticoids are more common in palatal mesenchymal cells, affecting the palatal
formation when corticosteroids are used in the first trimester of pregnancy 89, 90
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Caffeine
Bille et al. examined the association between the maternal lifestyle factors
during the first trimester and OFCs based on prospective data from the Danish
National Birth Cohort. Information on risk factors including tea, coffee, and cola
consumption was obtained during pregnancy for 192 mothers who gave birth to
children with an OFC while 828 mothers were selected as controls. The investigators
found no association with maternal coffee or cola drinking among the mothers of
affected infants. However, they found associations, although insignificant, with
maternal drinking of more than 11 colas per week as well as drinking five or more
cups of tea per day during the first trimester of pregnancy 91.
Another population based case-control study evaluated the association
between maternal consumption of coffee and caffeine from other types of beverages
in early pregnancy and the risk of delivering an infant with an OFC. Coffee
consumption during the first trimester was associated with an increased risk of CLP,
but not CLO, in a dose dependent manner. However, no evidence was found for an
association between other caffeinated beverages and the risk of CLP 92. Further,
Collier and colleagues (2009) investigated whether an association between maternal
intake of coffee, teas, sodas, chocolate, and medications containing caffeine in the
year before pregnancy and the risk of having a child with CL/P and CPO. The only
significant association was between Isolated CL/P and the use of medications
containing at least 100 mg of caffeine per dose 93.
Other environmental pollutants
A few epidemiological studies investigated the relationship between exposure
to environmental lead and birth defects and yielded inconsistent results 94. No effect
on prevalence at birth of major or minor anomalies has been noted in some studies,
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while other investigations reported an association between lead exposure and birth
defects 95. Vinceti et al. observed an excess risk of cardiovascular defects, OFCs, and
musculoskeletal anomalies in the lead polluted area 96. Additional environmental
exposures include some specific teratogens 66, 97 such as stress 98 and ionizing
radiation 99-101. Nonetheless, the harmful effects of these factors are still inconsistent
100

. Studies of gene-environment interaction may provide the understanding required

to explain such effects 58. However, the interaction between the studies of the
environmental risks and genes related to clefting require large prospective cohort
studies and access to genetic material to measure effects on clefting. Attempts at
identifying susceptibility loci via family and case-control studies have proved
inconsistency 102. Yet, this is a promising area of research that can be expected to
expand 103, 104. Thus, identification of the environmental risk, particularly if they can
be adapted with genetic modifiers, can be more flexible and provide the best shortterm opportunities to provide more insight into better understanding and prevention 58,
100

.

Maternal Vitamin and Mineral Nutrition
Observational studies suggest a role for maternal nutrition in OFC, even
though assessments of dietary intake or biochemical measures of nutritional status are
demanding and often not available in many of the impoverished populations with the
highest rates of OFCs 105.
Folate and nutrients related to one-carbon metabolism.
Case-control studies of folic acid-containing multivitamin (MVI) supplements
106-109

114

, maternal dietary folate intake 57, 107, 110-112, and red cell and plasma folate 43, 112-

are inconsistent. Bille et al. have found that supplementation use of folic acid with

400-mcg daily during the entire first trimester would have an inverse association
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with OFC 91. Furthermore, in a 2011 case-control study in Utah, even though there
were no differences in MVI use during pregnancy, case-mothers had significantly
lower plasma and red cell folate levels than did control mothers, and the mean
differences in folate levels between cases and controls widened years after the
affected pregnancy, suggesting that progressive disorder of folate metabolism may be
more common in case mothers compared to control mothers 34.
Smits and Hukkelhoven reported an increased risk of adverse birth outcome at
both ends of the interpregnancy interval spectrum, and a lower risk between 12 and
23 months. The authors hypothesized the increased risks associated with short
interpregnancy intervals are partly attributable to maternal depletion of
micronutrients, particularly folate 115. Pregnancy places a burden on maternal
micronutrient reserves and, if a new conception occurs before these reserves are
sufficiently restored, growth and development of the conceptus may be compromised.
Pregnancies accomplished shortly after the preceding delivery, in addition, are more
likely than others to be unintended 116, which decrease the probability of
periconceptional folic acid supplements (or MVI) use. However, Villamor et al.,
Krapels et al. and Wyszynski et al. suggested the risk of OFCs to be dependent on
periconceptional intake of folate and other micronutrients 111, 117, 118.
Other specific nutrients
Strong evidence suggests an association between OFCs and other nutritional
factors, including vitamin A, riboflavin, folic acid, panthothenic acid, vitamin B12,
vitamin B6, and zinc 111, 119, 120. Mothers of infants with CL/P have been reported to
have higher mean serum homocysteine levels 113, 114, 121. Vitamin B-6 (pyridoxine and
related compounds) is also a co-factor in homocysteine metabolism and reduces the
occurrence of CL/P in animal studies 114. Biomarkers of poor vitamin B-6 status were
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associated with an increased risk of CL/P in the Netherlands 113 and in the Philippines
43

.
Zinc is important during pregnancy for the fetal development; and zinc

deficiency causes CP and other malformations in animal studies 122. Mothers of
children with CL/P in the Netherlands had lower erythrocyte zinc levels than control
mothers. In Philippines, zinc deficiency is widespread, and higher maternal plasma
zinc levels were associated inversely with the risk of CL/P 120. However, in a casecontrol study in Utah, Munger et al. found no difference in plasma zinc levels
between case and control mothers 123.
Iron intake during pregnancy was also found to decrease the risk for OFCs 57.
Other nutrients that may be involved in the etiology of CL/P include vitamin B2 and
vitamin A 101. Bille et al., however, found no effect for vitamin A, B6 or B12 on the
occurrence of cleft 91.
According to a meta-analysis conducted in 2008 112, maternal use of MVI
supplements in early pregnancy may attenuate the birth prevalence of clefts by 25%.
A potential interaction between maternal hyperthermia during pregnancy and MVI
supplement use was indicated by two previous studies, suggesting that supplement
use reduces the increased risk of CL/P associated with hyperthermia 124, 125. On the
other hand, Czeizel et al. indicated that daily supplementation with MVI does not
have the inverse effect on the risk of clefts 126. It is difficult to determine whether this
reduction is due to the consumption of a specific nutrient or other healthy behaviors
confounded these results 112.
Additionally, several studies investigated whether the risk for birth defects
associated with maternal diabetes is attenuated by use of multivitamin supplements
during the periconceptional period. Mothers with diabetes were having an increased

25
risk of having offspring with selected birth defects. However, the effect appeared only
within mothers who had diabetes but were not taking MVIs, suggesting that MVI use
during the periconceptional period may reduce the risk for birth defects among
offspring of mothers with diabetes 127, 128
Maternal Obesity and Underweight
Obesity is a health condition in which excess body fat has accumulated,
leading to increased health problems such as heart disease and type 2 diabetes and
reduced life expectancy 129. Several factors including higher food energy intake with
reduced energy expenditure (sedentary life style) 130 and genetic susceptibility are
involved in obesity. In addition, pregnancy, in itself, is considered a risk factor for
obesity as the mother gain weight during pregnancy and become increasingly obese
with the frequent pregnancies, increasing the risk of congenital malformation and
stillbirth 131. Maternal underweight is associated with several adverse outcomes,
including low birth weight, anemia, and an increased mortality rate 132. Nevertheless,
it remains an understudied health problem 133.
A study intended to estimate the overall prevalence of overweight and obesity
in the world and in various regions in 2005 and to project the global burden in 2030.
Overall, 23.2% of the world’s adult population in 2005 was overweight with a higher
rate in men (24.0%) than women (22.4%). The overall prevalence of obesity in the
world, yet, was lower (9.8%) with a higher rate in women (11.9%) than obese men
(7.7%). The total number of overweight adults was projected to increase during the
period 2005 to 2030 from 937 million to 1.35 billion, while the number of obese
adults was expected to increase from 396 million to 537 million without adjusting for
secular trends 134. In addition, the incidence of obesity in pregnancy has increased
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over the past 2 decades; with nearly 50% of U.S. women aged 15-49 years classified
as overweight or obese 135.
Body-mass-index (BMI) is a screening tool calculated from an individual's
weight and height and defines people as overweight (pre-obese) if their BMI is
between 25 and 29.9 kg/m2, obese when it is greater than 30 kg/m2, and underweight
when it is less than 18.5 kg/m2 136. The BMI was originally invented by Adolphe
Quetelet in 1832, as the relation between body weight and mortality, particularly
cardiac disease and diabetes, gradually became a medical concern following the
Second World War, and thus, a quest for a reliable and practical index of relative
weight began to be increasingly important. Quetelet proposed that in adults, in
exploring various indices combining weight and height, normal body weight in
kilograms was proportional to the square of the height in meters 137, 138. Ancel Keys
(1904–2004) confirmed the validity of the Quetelet Index and named it the BMI 139.
Since then, as evidence of the association of obesity with various diseases continues
to increase, the BMI has been used as an expression to report the link of excess
relative weight to morbidity and mortality. Even though the generalizability and
applicability of the BMI and its cut-off points to other populations has been
questioned and its sensitivity as a measure of excess fat queried, it remains a
dependable value and the basis of much of the associations reported heretofore with
obesity 140.
Maternal obesity and DM have been hypothesized to act synergistically in the
pathogenesis of craniofacial abnormalities 141-143, and both maternal obesity 143, 144 and
underweight 145 have been found to be associated with CL/P, but these issues are still
insufficiently studied in OFC research 105.
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The prevalence of obesity is currently rising worldwide. The epidemic is
especially pronounced in women of reproductive age 146. A study conducted in 2012
aimed to estimate the prevalence of adult obesity from the 2009-2010 National Health
and Nutrition Examination Survey (NHANES) and compare adult obesity and the
distribution of BMI with data from 1999-2008. The age-adjusted prevalence of
obesity was 35.5% among adult men and 35.8% among adult women. Obesity
showed no significant increase among women overall through 1999-2010 (adjusted
odds ratio aOR=1.01 [95% CI 1.00-1.03]), but increases were statistically significant
for non-Hispanic black women and Mexican American women. Men presented a
significant linear trend through the period 1999-2010. For both men and women, the
most recent 2 years (2009-2010) did not differ significantly from the period 20032008. The prevalence of obesity was 35.5% among males and 35.8% among females;
and BMI trends were similar to trends in obesity 147. When the future prevalence and
BMI distribution was projected for 2010 to 2030, it was estimated that if the trends
continue, in only 15 years, 80% of all American adults would be overweight or obese
148

.
Maternal undernutrition is highly prevalent in low-income and middle-income

countries, resulting in significant increases in mortality and overall disease burden.
Undernutrition involves deficiencies of essential vitamins and minerals
(micronutrients) as one form of malnutrition, with obesity or over-consumption of
specific nutrients as another form 149 For instance, it has been reported that in many
areas of India people suffer from an under-nutrition problem 150. Nevertheless, Garg
et al. recommended immediate attention for the higher rate of obesity among Indian
women. Between the periods 1998–1999 to 2005–2006, the prevalence of obesity
increased by 24.52%. 23.7% of women aged between 40-49 years were reported to be
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obese. 23.5% of the obese residents reside in cities and 30.5% of them are wealthy.
Several life style factors, such as sedentary lifestyle and junk food habits contributed
to the increased prevalence in India 150. Another study comparing the prevalence of
obesity between men and women in Shahjahanpur City, India found the highest rate
to be in women at age 41-50 years (41.2%) and men at age 61-70 years (37.0%) 151.
A longitudinal prospective study conducted in 2011 has revealed that in
comparison to normal weight pregnant women, obese pregnant women were at
increased risk of gestational diabetes mellitus, pregnancy induced hypertension, preeclampsia, and postpartum infection morbidities. These women were more prone to
develop diabetes and chronic hypertension in the future as well 152.
As the prevalence of obesity has risen in developed countries, overweight
among pregnant women has become increasingly common 153. In the United States,
the incidence of obesity among pregnant women ranges from 18.5% to 38.3%,
according to the cohort studies and cutoff points used to define overweight 154, 155. In
Sweden, the prevalence of obesity among pregnant women was 26.1% 156, 157, while
in Netherlands and France, the prevalence reported to be 17% 158. Compared with
normal weight, maternal overweight is related to a higher incidence of premature
birth, congenital malformations, and infant mortality 158.
Maternal Obesity and Underweight and Cleft Lip and Cleft Palate Birth Defects
Maternal obesity is associated with an increased risk of several congenital
birth defects. The association is most pronounced for neural tube defects 159-163,
cardiac defects 141, 160, 162, 164, and orofacial cleft (OFC) defects 117, 141, 143, 162, 165-167.
However, many studies of maternal obesity and OFC risk were limited by the small
sample sizes. For instance, Waller et al. has investigated the association between
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maternal obesity, overweight, and underweight with distinct types of structural birth
defects. The results suggested a borderline increased risk of isolated cleft palate only
(CPO) within obese mothers (n=86; adjusted odds ratio (aOR)=1.27 [95% confidence
intervals (CI) 0.98-1.66]) and a significant increase in cleft lip with or without palate
(CL/P) within underweight mothers (aOR= 1.35 [1.04-1.76]) 162. A recent a
population-based case-control study conducted in Florida found obese women to
experience increased odds of having a child with CL/P after controlling for maternal
race, education, smoking, marital status, nativity, and maternal age (OR=1.25 [95%
CI 1.05-1.48] and CP, OR=1.32 [1.07-1.62]). However, in this same study, the
offspring of underweight mothers were not at a higher risk of OFCs 168.
Obese women were also reported by other studies to have high incidences of
birth injuries and congenital malformations particularly OFCs 152, 169. Mothers who
were underweight were reported to have no significant increase or decrease in the risk
for heart defects, hypospadias, omphalocele, or craniosynostosis birth defects, but did
not have a significant increase in risk for CL/P (adjusted OR1.35 [95% CI 1.04-1.76])
162

.
In a study consisting of 1,049,582 infants born in Sweden from January 1,

1995 through December 31, 2007, maternal overweight and obesity were associated
with an increased risk OFCs and the risk was increasing with the increased degree of
obesity 170. Another study conducted in Sweden consisted of 988,171 infants, where
OFCs were divided into: isolated CPO, CLO, and CL/P. The subjects were also
divided into isolated (without any other major malformation present) or non-isolated
(with other major malformations). In the maternal underweight group, no change in
the risk for an infant with cleft was observed. In the overweight group, the risk was
above one for CPO, CLO, CLP, and all CLs as well as for isolated and non-isolated
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defects separately. In the group of obese mothers, there was an overall increased risk
for infants with OFCs. The increased risk was higher when the OFCs were associated
with other major malformations than when they were isolated 171.
In Saudi Arabia in 2012, a study aimed at detecting the predictors of isolated
structural birth defects in live births. Out of 37,168 live births, isolated structural birth
defects were found in 318 cases. Obesity was a significant predictor for increased
facial defects (aOR=5.92 [95% CI 2.8–12.4]) 172.
In contrast to the studies described, Oddy and collegues reported an
insignificant increased risk of OFC associated with obesity (n=6; aOR=1.41 [0.852.34]) 173. Stott-Miller et al. also evaluated the effect of maternal obesity in relation to
the risk of non-syndromic orofacial clefting. Regardless of the type of cleft, obese
women had a small, non-significant increase risk of isolated OFCs in their offspring
compared with normal-body mass index women 174.
Villamor and Cnattingius have examined the associations between change in
pre-pregnancy BMI from the first to the second pregnancies, and the risk of adverse
outcomes during the second pregnancy in a nationwide Swedish study of 151,025
women who had their first two consecutive singleton births between 1992 and 2001.
The results supported the causal relation between being overweight or obese and risks
of adverse pregnancy outcomes. Additionally, they suggested that modest increases in
BMI before pregnancy could result in perinatal complications, even if a woman does
not become overweight 175. Similarly, Guelinckx reported a higher incidence of
premature birth, congenital malformations, and infant mortality among mothers with
increased BMI 153. Cedergren and Kallen have regarded the positive association
between maternal obesity and OFCs risk to the undetected type-2-diabetes mellitus
within obese mothers 171.
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Maternal Diabetes
Diabetes mellitus (DM) is a group of metabolic diseases resulting from defects
in insulin secretion, insulin action, or both and characterized by chronic
hyperglycemia with disturbances of carbohydrate, fat and protein metabolism. Three
main types of diabetes have been defined: type-1, type-2, and gestational diabetes
mellitus (GDM) 176. Type-1 diabetes mellitus or insulin-dependent diabetes mellitus
(IDDM) is partly inherited and then triggered by certain infections. It results from a
T-cell mediated autoimmune destruction of the pancreatic beta cells in genetically
predisposed individuals 177. Type-2 diabetes or non-insulin-dependent diabetes
mellitus (NIDDM) is due primarily to lifestyle factors and genetics 178. Type-1 and -2
are both conditions that usually cannot be reversed. Hence, adherence to healthy diet,
exercise, and use of appropriate medications is very important to keep blood sugar
levels as close to normal "euglycemia" and avoid diabetes complications 179.
Gestational diabetes mellitus (GDM) is a condition in which women without
previously diagnosed diabetes exhibit high blood glucose levels (particularly during
third trimester of pregnancy) when their bodies do not secrete the adequate insulin
required during pregnancy 180. Yet, mothers with GDM are at high risk for having or
developing diabetes after their pregnancy 181. There is a very close relationship
between GDM and Type 2 diabetes; GDM is considered to be a transient unmasking
of an underlying predisposition to Type 2 diabetes, induced by the metabolic changes
of pregnancy 182
Diagnoses of Diabetes
According to the American Diabetes Association (ADA), an individual can be
diagnosed with DM in any one of the four methods: (1) Glycosylated hemoglobin, or
hemoglobin A1C, of ≥ 6.5%; (2) Fasting Plasma Glucose (FPG) of ≥ 126 mg/dL; (3)
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two-hour plasma glucose of ≥ 200 mg/dL during an Oral Glucose Tolerance Test
(OGTT); or (4) classic symptoms of hyperglycemia or hyperglycemic crisis
(polydipsia, polyuria, and unexplained weight loss) accompanied by a random plasma
glucose of ≥ 200 mg/dL. However, different diagnoses criteria of GDM have been
identified 183. For instance, the World Health Organization (WHO) in 2006 has
developed a different diagnostic criteria with lower glucose cut-off values for GDM
than the ones reported by the ADA and demonstrated that GDM should be diagnosed
at any time in pregnancy if one or more of the following criteria are met: (1) FPG of
92 -125 mg/dl); (2) one-hour plasma glucose of 180 mg/dL following a 75g OGTT; or
(3) 2-hour plasma glucose 153 -199 mg/dL following a 75g OGTT. These guidelines
are based on the association of plasma glucose and adverse maternal and neonatal
outcomes during pregnancy, at birth and immediately following it 184.
Diabetes first onset during pregnancy was recognized and termed “GDM” in
the 1950s 185. GDM was originally defined to identify pregnant women who are at a
higher risk for developing Type-2 diabetes later in life. The diagnosis is now being
used to predict many potential neonatal and maternal complications in pregnancy 186.
The prevalence of GDM varies greatly from 1 to 16% depending on the population
studied and the diagnostic criteria used 187. For several years, the diagnosis of GDM at
the local hospitals was made by a 100-g oral glucose tolerance test (OGTT) using the
ADA criteria based on the “selective screening,” which is a selective strategy to
detect GDM among older or obese women 188. However, the 100-g glucose load
caused vomiting in nearly 10% of the women undergoing the OGTT 189. Therefore,
after the ADA endorsed the 75-g OGTT for the diagnosis of GDM, it was decided to
screen all women not previously known to have diabetes using the 75-gram OGTT
between 24 and 28 weeks of gestation and using diagnostic cut points of greater than
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92 mg/dl for the fasting glucose test; greater than 180 mg/dl one hour after drinking
the 75-gram glucose solution; and greater than 153 mg/dl two hours after drinking the
glucose solution 183.
Epidemiology of Diabetes
Diabetes mellitus is one of the most common chronic diseases in nearly all
countries, and continues to increase in numbers and significance, as changing
lifestyles lead to reduced physical activity, and increased obesity 190. The current
estimate of diabetes prevalence worldwide was reported by the World Health
Organization (WHO) to be 171,000,000, while it is projected that in 2030, the
prevalence will increase to 366,000,000 191. Compared to estimates reported by
previous studies, the prevalence of diabetes worldwide is significantly increasing. In
1995, one worldwide study has projected the number of people with diabetes in all
countries of the world for three points in time, the years 1995, 2000, and 2025. The
prevalence of diabetes in adults worldwide was expected to be 4.0% (135 million) in
1995, with a higher prevalence within females than males with diabetes (73 vs. 62
million). However, the prevalence of diabetes was expected to rise to 5.4% (300
million) by the year 2025, showing a 35% increase in the worldwide prevalence of
diabetes, with a somewhat reduced excess within females than males (159 vs. 141
million) 192, 193. Another study projected that in 50 years the number of American with
diagnosed diabetes will increase 165%, from 11 million in 2000 to 29 million in 2050
with a higher prevalence in females than in males after the age of 64. This study
predicted that 37% of the 18 million increase in 2025 would be due to changes in
demographic composition, 27% due to population growth, and 36% are due to
increasing prevalence rates 194. Another study projected an increase of diagnosed
diabetes prevalence from 4.4% (12.0 million) in 2000 to 9.7% (39.0 million) in 2050
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195

. In 2011, a follow-up epidemiological study evaluated the current prevalence of

NIDDM in Saudi Arabia. The age-adjusted prevalence of NIDDM was 31.6% with a
significantly higher prevalence in men (34.7%) than in women (28.6%) 196.
The frequency of GDM usually reflects the frequency of NIDDM in the
underlying population 197, 198. Established risk factors for GDM include advanced
maternal age, obesity, and family history of diabetes 180. Xiong et al. estimated the
prevalence, risk factors, and maternal and infant outcomes of mothers with GDM in a
retrospective cohort study, based on 111,563 pregnancies delivered between 1991
through 1997 in 39 hospitals, in northern and central Alberta, Canada. The prevalence
of GDM was 2.5%. Risk factors for GDM included age over 35 years, obesity, history
of prior neonatal death, and prior cesarean section. Teenage mothers and women who
consumed alcohol were less likely to have GDM. Mothers with GDM were at
increased risk of presenting with pre-eclampsia, premature rupture of membranes,
cesarean section, and preterm delivery. Infants born to mothers with GDM were at a
higher risk of being large-for-gestational-age 199.
Maternal Diabetes and Cleft Lip and Cleft Palate Birth Defects
Animal Studies
Abundant clinical evidence indicated that diabetic mothers are at a high risk of
having malformed offspring 200, 201 and that congenital malformations contribute to
the high neonatal loss among infants born to diabetic mothers 202. Watanabe and
collegues conducted an experiment to study the teratogenic effects of alloxan diabetes
upon the mouse embryo. CP was found to be induced in embryos of alloxan-diabetic
females, with the type and frequency of deformities being dependent upon the timing
of alloxan injection 203.
Ejdesjo et al. investigated the influence of parental transgenerational genetics
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and maternal metabolic state on fetal deformity in diabetic rat pregnancy. Rats from
an inbred malformation-resistant (W) strain, and an inbred malformation-prone (L)
strain, were cross-mated to produce two different F1 hybrids, WL and LW. Normal
(N) and manifestly diabetic (MD) WL and LW females were mated with normal
males of the same F1 generation to obtain WLWL and LWLW F2 hybrids. Maternal
diabetes increased malformation and resorption rates in both F2 generations. MDWLWL offspring had higher resorption rate but a similar malformation rate compared
with the MD-LWLW offspring. Such results imply a possible teratological
mechanism in diabetic pregnancies that are influenced by maternal metabolism and
parental strain epigenetics 204. In contrast, an experiment was conducted to investigate
whether congenital malformations in offspring of alloxan-diabetic mice can be
prevented by insulin injections of 80 mg per kg of bodyweight during pregnancy. In
50 successful pregnancies treated with insulin, only one fetus (0.2%) of 472 was
malformed with a cleft palate; in 50 successful pregnancies given alloxan alone, 14
(28%) of mice had one or more malformed fetuses. Altogether, six of 437 fetuses had
CP. The difference between the alloxan group and insulin treated group in the number
of mothers having malformed fetuses, and in the number of malformed fetuses
produced was statistically significant according to the chi-square test with a
probability level of less than 0.01. However, no significant correlation was observed
between the magnitude of hyperglycemia of mother mice and the frequency of fetuses
with congenital malformations 205.
Human Studies
Diabetes Mellitus (DM) has been identified as independent risk factors for
several birth defects, providing support for a mechanism that involves hyperglycemia
and hyperinsulinemia in the development of malformations 206, 207. Mothers who
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develop GDM later in pregnancy may have had undiagnosed type-2 DM and are
susceptible to acquire DM later in life 208. However, it is debated whether this is true
also at gestational diabetes 209.
A population-based case-control study was conducted to investigate the
association between maternal DM and the risk of OFCs in the offspring using the
1996 National Center for Health Statistics United States Natality database. The
sample consisted of 2,207 live births with CL/P and 4,414 randomly selected live
births controls. Results indicated an increased risk for CL/P among diabetic mothers
compared to non-diabetic mothers (adjusted odds ratio (aOR)=1.35 [95% confidence
interval (CI) 1.00–1.82]) 210. In a retrospective cohort study consisted of 126 nonsyndromic cleft cases, the association between maternal diabetes mellitus and the risk
of OFCs was evaluated. Results indicated a significant increased risk of isolated CP
within diabetic mothers 211. CP has been also reported by Arteaga to have a higher
frequency in congenital malformation than in the rest of malformed newborns of nondiabetic mothers 212.
Data from the National Birth Defects Prevention Study from 1997 to 2007
were used to investigate the association between maternal Dietary Glycemic Index
(DGI) and the risk of birth defects among non-diabetic women. Among the 53 birth
defects analyzed, high DGI was significantly associated with encephalocele and atrial
septal defect. Using quartiles to categorize DGI, the authors identified associations
with CLP and anorectal atresia/stenosis. The joint effect of high DGI and obesity
provided evidence of a synergistic effect on the risk of selected birth defects. High
DGI was associated with an increased risk of a number of birth defects. Obesity
coupled with high DGI appeared to further increase the risk for some birth defects 213.
Additionally, using dietary data collected in the Boston University Slone
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Epidemiology Birth Defects Study, Yazdy et al. examined the effect of a high dietary
glycemic index (dGI) or load (dGL) on the risk of birth defects. High DGL intakes
were more common than controls for OFC case groups, but the Odds Ratio (OR)
estimates were unstable due to small population size 214.
In 2002, a study was conducted to investigate the frequency of hyperglycemia
in pregnant women who were without health benefits and did not receive prenatal
specialist care. Clinical characteristics of newborns show statistically significant
increased risk of CLP in offspring whose mothers had inadequate prenatal care
compared to of infants whose mothers had regular prenatal care, suggesting a
necessity to start establishing new programs and ways of making health information
available to women in primary care clinics to educate the general population and
stress the importance of regular visits to a prenatal care specialist 215.
Goldman et al. investigated whether arachidonic acid is involved in processes
analogous to neural tube folding and fusion in diabetic mothers. This hypothesis was
raised by the role of arachidonic acid in palatal elevation and fusion. The study
suggested that the mechanism of mediating the teratogenic effect of an increased
glucose concentration involves a functional deficiency of arachidonic acid at a critical
stage of organogenesis 216.
Furthermore, a Turkish congenital malformation survey revealed a
significantly frequent incidence of CPO. Abnormal ultrasonographic findings and
disorders such as DM and GDM were found to be valuable indicators for the presence
of congenital malformations in the fetus 217.
Janssen et al. investigated the association between GDM and the development
of congenital malformations from a populations-based retrospective study. Data for
births to mothers with established diabetes were also available. Newborns of mothers
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with established diabetes were more likely to have a congenital malformation than
newborns of non-diabetic mothers. On the other hand, there was only a slightly higher
prevalence of congenital malformations among newborns of mothers with GDM. The
association with maternal established diabetes was greater for neonates with multiple
malformations than for single malformations. Four to seven fold associations were
observed with skeletal, neural tube and heart abnormalities, and CL/P. The
association of established diabetes with congenital malformations was nearly twice as
strong among female neonates than among male neonates and no such variation was
observed for associations with GDM 218. In addition, based on a cohort study of 2,060
infants to mothers with GDM, congenital malformations, including CL/P, have been
correlated to pre-pregnancy BMI and to the severity of diabetes 142.
The risk of birth defects was investigated by Correa et al. (2012) in relation to
DM and the lack of use of periconceptional vitamins or supplements containing folic
acid using a population-based case-control study. Among 14,721 cases and 5,473
controls, the risk of OFCs associated with DM in the absence of periconceptional use
of MVIs containing folic acid increased significantly (ratio of 11:2 (cases: controls)
and aOR of 13.84 [95% CI 3.01-63.68]) compared to mothers with DM and reported
periconceptional MVI use (ratio of 23:27 and aOR of 2.17 [95% CI 1.20-3.93]). This
result suggests that the periconceptional use of MVI may reduce the risk for birth
defects among offspring of mothers with diabetes 127, 128.
Abdominal obesity, aberrant glycemic control, hypertension, and
hyperlipidemia are variably defined as a co-occurrence of metabolic syndrome 219.
Some of the common co-morbidities of this diagnosis include increased oxidative
stress and inflammation and compromised immune function 220. Investigation of this
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syndrome, with the presence of obesity, DM, and hypertension may provide useful
clues regarding birth defects associations 98.
Previous studies have suggested an increased risk for having newborns with
OFCs in diabetic mothers compared to non-diabetic mothers 207, 211, 221, 222. Although
GDM has been also reported by previous studies to increase the risk for congenital
birth defects 223-225, studies of the association between GDM and OFC are limited.
Investigating the effect of maternal DM and GDM on the risk of OFC specific types
may provide useful clues regarding the risk factors associated with the etiology of
OFCs.
Hypertension
Hypertension is a chronic medical condition in which the systemic arterial
blood pressure is elevated to a level that may induce adverse effects such as
cardiovascular damage. Normal blood pressure is 120/80 mm/Hg. High blood
pressure is anything more than 140/90 mm/Hg. Dietary and lifestyle changes can
improve blood pressure control and decrease the risk of associated health
complications 226. Although no direct cause has been identified, there are many
factors such as sedentary lifestyle, smoking, stress, hypokalemia 227, salt (sodium)
sensitivity 228, alcohol intake 229 and vitamin D deficiency that increase the risk of
developing hypertension 230. Hypertension is also caused by other conditions such as
obesity 231. Lifestyle modification including dietary changes, physical exercise, and
weight loss has been proven to significantly reduce blood pressure in people with
hypertension 232.
Epidemiology of Hypertension

Hypertension affects millions of persons in the United States, and less
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than half of those with hypertension have their condition controlled. Using the
National Health and Nutrition Examination Survey (NHANES) data, several studies
have been conducted to estimate the prevalence of hypertension in the United States.
A study has used the NHANES Survey 1999–2004 database, and found the overall
prevalence of hypertension to be 29.3%. When compared with the 1999–2000 data
set, there were non-significant increases in the overall prevalence of hypertension 233.
A more recent study reported the prevalence of hypertension in the United States.
During 2005-2008, approximately 68 million (31%) U.S. adults aged ≥18 years

were having hypertension, and this prevalence has shown no improvement in
the past decade and of these adults, 86% had their condition uncontrolled 234.
In 2012, a study was conducted to examine the prevalence and outcomes of
primary and secondary chronic hypertension using a population-based sample of
deliveries. During 1995-2008, the prevalence of primary and secondary hypertension
increased significantly from 0.90% in 1995-1996 to 1.52% in 2007-2008 and from
0.07% to 0.24%, respectively. Primary and secondary chronic hypertension were
considerable for many maternal adverse outcomes, including acute renal failure,
pulmonary edema, and preeclampsia, and accounted for a significant fraction of
pregnancy complications 235.
Maternal Hypertension and Cleft Lip and Cleft Palate Birth Defects
Pregnancy in women with hypertension has various neonatal complications
236

. However, the effect of maternal hypertension of the risk of congenital

malformations, including OFCs, has been understudied 237. In a study conducted to
explore possible maternal factors associated with OFCs in the US population, the
prevalence of pregnancy-associated hypertension was significantly higher in OFC
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group compared to controls. After adjustment for maternal age and tobacco smoking,
multivariate models found Non-Hispanic Blacks with pregnancy-associated
hypertension to be at lower risk for having a child with an OFC (aOR=0.09 [95% CI
0.02-0.42]) as well as Hispanics (OR=0.79 [95% CI 0.63-0.98]). Researchers in this
study suggested a role of the epigenetic DNA modification resulted from the noninherited (modifiable) factor, the pregnancy-associated hypertension, in determining
whether the genes that direct the proper formation of the lip and palate are properly
expressed 56.
A case-control study conducted in Thailand sought to identify the risk factors
for congenital malformations between May 1987 to April 1988. CLPs were among
the most common types of malformations. Risk factors significantly associated with
malformations included maternal hypertension during pregnancy, maternal age > 35
years, low maternal education levels, separated or divorced marital status, family
history of similar abnormalities, an accident during pregnancy, and maternal illness
during pregnancy 238.
Although hypertension has been associated in a few studies with congenital
malformations, maternal hypertension and the risk of having offspring with OFCs
have been relatively understudied. Further investigation of this association may help
in reducing the risk of OFCs.
Metabolic Syndrome
Metabolic syndrome is a combination of medical disorders that, when cooccurring together, increase the risk of developing cardiovascular disease and
diabetes 239, 240. In 2001, the Third Report of the U.S. National Cholesterol Education
Program Expert Panel on Detection, Evaluation, and Treatment of High Blood
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Cholesterol in Adults (NCEP/ATP III) provided a working definition of the metabolic
syndrome based on five commonly measured clinical criteria and it requires at least
three of the risk factors to be present: 1) central obesity: waist circumference ≥
102 cm or 40 inches (male), ≥ 88 cm or 36 inches (female); 2) dyslipidemia: TG ≥
1.7 mmol/L (150 mg/dl); 3) dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL
(female); 4) blood pressure ≥ 130/85 mmHg; 5) fasting plasma glucose ≥ 6.1 mmol/L
(110 mg/dl) 241. In 2004, the American Heart Association intended to update the
NCEP ATP III definition as follows: 1) Elevated waist circumference: > 40 inches or
102 cm (male), > 35 inches or 88 cm (female); 2) Elevated triglycerides: ≥ 150 mg/dL
(1.7 mmol/L); 3) Reduced HDL (“good”) cholesterol: < 40 mg/dL (1.03 mmol/L)
(male), < 50 mg/dL (1.29 mmol/L) (female); 4) Elevated blood pressure: ≥
130/85 mm Hg or use of medication for hypertension; 5) Elevated fasting glucose:
≥100 mg/dL (5.6 mmol/L) or use of medication for hyperglycemia 242. The most
recent definitions, though, are from the International Diabetes Federation (IDF) and
from the American Heart Association/National Heart, Lung and Blood Institute
AHA/NHLBI 243-245. The differences between these definitions are essentially the
threshold for the parameters to define a syndrome abnormality, the number of
abnormalities before the syndrome is deemed to be present, and whether there is a
compulsory abnormality that is required to be present 246.
Since 1947, several studies suggested that early onset of obesity, hyperplasia
of normal adipocytes, and normal quantities of visceral abdominal fat may be
associated with a favorable metabolic response in obese subjects 247, 248. Keyes
suggested that obesity for some was not a risk factor and might even be healthy 249.
Bonora et al. concluded that a subgroup of obese individuals with a normal metabolic
response is evident 250. Brochu et al. have also suggested that obese metabolically
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normal subgroups must be taken into consideration in both clinical and research work.
In fact, attempts at weight loss may be counterproductive 251. Kip et al. conducted a
study to assess whether the contribution of obesity to cardiovascular risk is
independent of the presence of metabolic syndrome. Data revealed that metabolic
syndrome, but not BMI, predicts future cardiovascular risk in women. Results also
indicated that normal-weight women with the metabolic syndrome have a
significantly higher cardiovascular risk. However, overweight and obese women with
normal metabolism have a relatively low cardiovascular risk. A possible explanation
suggested by Kip et al. was that the measurement of BMI to define overweight and
obesity does not quantify the magnitude or ratio of subcutaneous to visceral fat or
muscle in an individual. The visceral fat area appears to be an important link between
many components of the metabolic syndrome, such as dyslipidemia and hypertension.
For a better precise clinical measurement, it is important to assess whether the
participants with normal BMI and the metabolic syndrome have relatively high levels
of visceral fat or, conversely, whether obese individuals with normal metabolic status
have relatively low levels of visceral fat 252.
Epidemiology of Metabolic Syndrome
Many reports were undertaken to explore the prevalence of the metabolic
syndrome around the world. However, the prevalence rates of the metabolic
syndrome reported in the different studies have varied widely, mainly because of
differences in the criteria used for defining the syndrome and the differences in the
characteristics of the populations studied 253.
Metabolic Syndrome in United States and Canada
Between NHANES 1988 to 1994, more than 25% of the population in the
United States had metabolic syndrome by NCEP criteria. A similar prevalence was
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described for Canada. By the age of 60, the percentage affected in the United States
increased to 40% 219.
In 2003 to 2006, 34% of adults met the criteria for metabolic syndrome. Males
and females between 40-59 years of age were about three times as likely as those 2039 years of age to meet the criteria for metabolic syndrome. By the age of 60, males
were four times as likely as the youngest group to meet the criteria, while females
were more than six times as likely. Non-Hispanic black males were about 50% as
likely as non-Hispanic white males to meet the criteria for metabolic syndrome, while
non-Hispanic black and Mexican-American females were about 150% as likely as
non-Hispanic white females to meet the criteria. Overweight males were six times as
likely while obese males were 32 times as likely as normal weight males to meet the
criteria. Overweight females were about five times as likely as normal weight females
to meet the criteria and obese females were more than 17 times as likely 254.
Metabolic Syndrome in Europe
Several studies on the occurrence of the metabolic syndrome in Europe have
been reported and the criteria used to define the metabolic syndrome varied across the
studies 255-265. However, it can be estimated that approximately 25% of the adult
European population had the metabolic syndrome. Prevalence varied across the age
group studied and geographic location. When NCEP and IDF criteria were compared,
the IDF criteria usually gave a higher prevalence 253.
Metabolic Syndrome in Latin America
According to a meta-analysis 253, the prevalence of the metabolic syndrome, as
defined by NCEP or WHO, is relatively high. Approximately 25% of the adult
population had the metabolic syndrome, with the highest prevalence contributing to
the Brazilian population (53%) 266.
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Metabolic Syndrome in Asia
The prevalence of metabolic syndrome was reported by several studies in
Central Asia, Southeast Asia, China, and Japan. In India, A cross-sectional population
based study reported the prevalence of metabolic syndrome in a local population in
India. Out of 1,568 patients were referred to High Tech Hospital, 33.17% of males
and 27.04% of females were diagnosed to have metabolic syndrome 267. Furthermore,
a population-based survey of cohort of subjects in the Metropolitan city of Mumbai
reported that 19.52% out of 548 subjects to have Metabolic syndrome. The overall
prevalence of BMI (>23 kg/m2) was 79.01% 268. In Southeast Asia, less than one-fifth
of the studied population in Southeast Asia had the metabolic syndrome 269, 270. In
China, the general population had a relatively low prevalence, possibly because of the
high waist circumference cut-off value of NCEP that was used for abdominal obesity
criterion. In older Chinese subjects with type-2 diabetes, the prevalence was much
higher 271-273. Finally, in Japan, the reported prevalence varied substantially from one
study to another. Surprisingly, two reports in men indicated a prevalence up to 25% of
the population 274, 275
Metabolic Syndrome in the Middle East
In the Eastern Mediterranean region, a study of adult female Saudi subjects
found the prevalence of metabolic syndrome to be 16.1% and 13.6% according to IDF
and ATP III definitions, respectively 276. The prevalence of metabolic syndrome in the
Arab Gulf countries was 10%–15% higher than in most developing countries, with a
higher prevalence among women. The proportion of metabolic syndrome in the Arab
Gulf countries ranged from 20.7% to 37.2% using ATP III definition, and from 29.6%
to 36.2% using the IDF definition 277.
In conclusion, the overall prevalence of the metabolic syndrome
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demonstrates that metabolic syndrome is prevalent worldwide and that it increases
with age and with BMI. The prevalence varied by race and ethnicity but the pattern
was different for males and females.
Metabolic Syndrome: The Underlying Causal Mechanism Linking Maternal Obesity,
Diabetes, and Hypertension to OFCs?
There is a common link between hypertension, diabetes, and obesity
illustrated by the causal relationship between the level of circulating insulin and
diastolic pressure caused by obesity 278. Abdominal obesity, glucose intolerance,
hypertension, and dyslipidemia are risk factors that comprise metabolic syndrome 279.
The increasing global prevalences of NIDDM and hypertension are a result of rising
rates of obesity 280, as well as hypertension 231 and have all been implicated in the
development of congenital defects 141, 238. Obese women are at higher risk for
developing NIDDM and, through pregnancy, at higher risk of developing GDM.
Women who develop GDM later in pregnancy may also have had undetected
metabolic problems earlier in the pregnancy 208. Since 1970, Navarrete et al. indicated
a definitive relation between a maternal glucose metabolic disorder and congenital
malformations and suggested research into the early phases of diabetic states in
mothers pregnant of a deformed infant 281. However, obese women, even in the
absence of diabetes, have been found to have impaired glucose metabolism 208. Forest
et al. have revealed that among white women in their mid-30s, the prevalence of the
metabolic syndrome is 3- to 5-fold increase in those with a history of pregnancyinduced hypertension in their first pregnancy 282.
McCarthy 130 has suggested that NIDDM results when pancreatic beta cells
are unable to secrete sufficient insulin to maintain normoglycemia, typically in the
context of increasing peripheral insulin resistance. The beta-cell abnormalities
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fundamental to type-2 diabetes are thought to include both reduced beta-cell mass and
disruptions of beta-cell function. Insulin resistance can be the consequence of obesity
or of obesity-independent abnormalities in the responses of muscle, fat, or liver to
insulin. Examples of susceptibility factors, given current evidence, that are likely to
influence predisposition to OFCs by means of each of these mechanisms are shown
(Figure 2-1).
Abdominal obesity, aberrant glycemic control, and hypertension are variably
defined as a co-occurrence of metabolic syndrome 219 and are substantially
interrelated, reflecting substantial overlap in their etiology and mechanisms 283.
Studies of the association between maternal bodyweight categories, DM and GDM,
and hypertension and the risk of specific OFC types may substantially reduce the risk
of OFCs associated with these conditions.
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Figure 2-1. Pathways to Type-2 Diabetes Implicated by Identified Common
Variant Associations 130
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CHAPTER 3
MATERNAL OBESITY AND UNDERWEIGHT AND THE RISK OF
OROFACIAL CLEFTS1
Abstract
Objective To evaluate whether maternal underweight and obesity are independently
associated with risk of orofacial clefts.
Design Pooled analyses of population-based case–control studies.
Setting A unique and large international consortium of case-control studies from
Utah, Iowa, Norway (two studies 1996-2001 and (2000-2009)), and the U.S. National
Birth Defects Prevention Study.
Participants Mothers of 2,162 infants with cleft palate and cleft lip (CLP); 1,161
infants with cleft lip only (CLO); 1,774 infants with cleft palate only (CPO); and
10,633 controls.
Main outcome measures Association of orofacial clefts with maternal pre-pregnancy
weight classified by the body-mass index (BMI, kg/m2) for underweight, normal
weight, overweight, and obesity.
Results Maternal obesity (pre-pregnancy BMI >30), compared to normal weight
(18.5<BMI>25), was associated with an increased risk of cleft palate with or without
cleft lip (CP/L) (aOR=1.13 [95%CI 1.01-1.25]), after adjusting for maternal age,
multivitamin use, smoking during pregnancy, alcohol use, and education level. We
also found a marginal association between maternal underweight and CP/L (1.0
[reference]; aOR=1.14 [95%CI 0.97-1.34]. CLO was not associated with underweight
or obesity. Among college-graduates, there was no increased risk of cleft palate for
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either underweight (aOR= 0.84 [95% CI 0.58-1.21]) or obesity (aOR =1.01 [95% CI
0.79-1.28]), but mothers with less than a completed college education had an
increased risk of cleft palate for underweight (aOR =1.26[95% CI [1.05-1.51]) and
obesity (aOR=1.17 [95% CI 1.05-1.32]).
Conclusions Maternal obesity and underweight are both similarly associated with
increased risk of orofacial clefts. These deviations from normal weight likely
represent diverse metabolic, dietary, socioeconomic, and lifestyle factors that may be
related to the causes of orofacial clefts. Interestingly, we found significant
modification of the associations between maternal underweight and obesity and cleft
risk by maternal education levels. Further analyses are needed to identify the
pathways leading to the increased risk for orofacial clefts and more detailed
assessment of socioeconomic status is needed. Our findings suggest that BMI may be
an imprecise indicator of risk and there is a need to assess mothers for hyperglycemia
and other underlying metabolic abnormalities early in pregnancy to reduce the risk of
orofacial cleft in their offspring.
Introduction
Clefts of the lip and palate are among the most common structural birth
defects and a public health problem 1, 2. In 2010 in the United States, an estimated
4,437 live births per year had cleft lip or cleft palate 3. Several studies suggest that
obesity, diabetes, or the underlying metabolic abnormalities known as the metabolic
syndrome, may be involved in the pathogenesis of cleft lip and cleft palate 4-6.
However, further studies are needed for a more complete understanding of the
etiology of this disorder 7.
Maternal obesity in early pregnancy has been associated with an increased risk
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of orofacial clefts (OFCs) in some studies. Yet, the magnitude of effect has varied
across studies and the question remains unresolved 8-12. This question is especially
relevant as obesity is leading global public health problem. Thus, even a modest
effect of maternal obesity may be linked to a significant burden of OFCs. The role of
maternal underweight is relatively understudied although it has potential adverse
perinatal outcomes 13. While underweight is a lesser problem in industrialized
countries, a better understanding of the role of underweight may help in
understanding the causes of OFCs in both industrialized and developing countries.
Obesity is usually defined as having a body-mass-index (BMI; weight in
kg/height in M2) of >30.0 kg/m2 14. Among adults, age-adjusted prevalence of obesity
in 2007-2008 was 33.8%, with an overall 32.2% among men and 35.5% among
women 14. It is expected that by 2015, 41% of adults in the United States will be
obese 15. An increased bodyweight is associated with increased incidence of a number
of conditions, including diabetes mellitus and cardiovascular disease. An increased
risk for diabetes mellitus begins to rise at a BMI of greater than 30 kg/m2 16. Other
risk factor that may contribute to a higher obesity risk is low educational attainment
of mothers 17. We assessed the relationship between maternal BMI and the risk of
clefts in a consortium of studies from Utah, Iowa, Norway, and the U.S. National
Birth Defects Prevention Study.
Methods
Study Design & Data Collection
This study is a combined, unique, and large international consortium of
population-based case-control studies from two separate studies from Iowa, Utah, the
U.S. National Birth Defects and Prevention Study (NBDPS), and two Norwegian
studies. The combined sample includes 15,726 women including 5,093 mothers of

72
children with OFCs and 10,633 mothers of unaffected children. Table 3-1 summarizes
the types of clefts, the numbers, and the sources of samples. Data were available on
self-reported pre-pregnancy maternal weight and height and other perinatal and
demographic factors, which are used as covariates to control for potential
confounding. Body-mass index (BMI) was computed as weight (kg)/height (m2) and
used to define body weight categories as underweight (BMI<18.5 kg/ m2), normal
weight (18.5-<25 kg/ m2), overweight (25-<30 kg/ m2) and obese (≥30 kg/ m2).
Studies included in this current study are as follows:
(1) Utah Study: A state-wide case-control study of clefts was conducted in
Utah during 1995 to 2004 in collaboration with the Utah Birth Defects Network
(UBDN) involving 561 cases with CL/P and 660 randomly selected unaffected births
(from birth certificates) matched cases by month, year of birth, and gender of the
child. The UBDN staff members attempted to contact potential case and control
mothers by mail to obtain consent for release of their names to USU investigators.
Address updates were sought using available Internet services. If no mailing address
was available, attempts were made to locate the mothers in person by field tracing
that included visits to the last known home address and inquiries with neighbors. The
UBDN later joined the National Birth Defects Prevention Study (NBDPS) described
below. A detailed description of data collection is provided elsewhere 18.
(2) Norway Facial Cleft Study: The Norway Facial Clefts Study (NCL) is a
population survey of infants born with CL/P in Norway in 1996 through 2001. Data
included 570 cases and their parents and a randomly selected control sample of 736
infants born without birth defects in the same period 19. Extensive data on maternal
behaviors, household factors and socioeconomics were available. The data collection
is described elsewhere 20.
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(3) Norway National Mother and Child Cohort Study: The Norwegian Mother
and Child Cohort Study (MoBa), conducted by the Norwegian Institute of Public
Health (NIPH, Oslo, Norway), is a cohort consisting of pregnancies recruited
beginning in 1999 to 2008 21. Identified were 164 cases of C/P and 551 control
mothers of which were randomly selected with matching to the case sample by year
and state of birth. Data on maternal health behaviors, demographic and
socioeconomic characteristics, health problems and food behaviors were obtained
during pregnancy between weeks 15 and 30 (data on risk and health behaviors is
collected between 15 and 18 weeks). The study also involved follow-up interviews
with the mother and child until the child is three years old.
(4) Iowa Case-Control Sample: The Iowa Registry of Congenital and Inherited
Disorders (IRCID) case-control sample consisted of about 287 cases with CL/P and
302 controls born between 1987 through 1996. The control sample was randomly
selected from all unaffected live births and matched to the affected sample by birth
month, year and gender. Data on risk behaviors, socioeconomic characteristics and
other relevant data, were obtained through telephone-based interviews and selfadministered forms were sent by mail 22.
(5) National Birth Defects Population Studies: NBDPS samples with CL/P and
control samples included multiple participating States. These include Arkansas,
California, Georgia, Massachusetts, New Jersey, New York, North Carolina, Iowa,
Texas, and Utah. NBDPS sample provided 3,491 CL/P cases and 8,357 control
mothers, matched by State and birth year to the CL/P sample 23.
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Table 3-1. Number of Controls and Orofacial Cleft Cases by Cleft Type and Study
Site
Number of study participants by cleft type
Site and Birth years
Utah, USA
(1995-2004)
Norway Case-Control Study
(1996-2001)

Controls

Cleft Lip Cleft Lip Cleft Palate
Only
and Palate
Only

All Clefts

660

142

232

187

561

763

140

234

196

570

Norway Mother-Baby (MoBa) Study
(2000-2009)

551

31

94

63

184

Iowa, USA
(1987-1991)

302

56

111

120

287

U.S. National Birth Defects Prevention Study
(1997-2008)

8357

792

1491

1208

3491

Total sample

10633

1161

2162

1774

5093

Statistical Analyses
SPSS statistical analysis version 20.0 was used to describe the characteristics
of study population. Descriptive analysis was conducted in SPSS to examine the
association between obesity and other factors, such as maternal age, smoking during
pregnancy, multivitamin use, education (college graduate, high school graduate only,
and less than high school graduate) and socioeconomic status.
Analysis of variance was used to examine the association between body mass
index (BMI) and each selected covariates, such as maternal age, study site, smoking
during pregnancy, multivitamin use, education, and socioeconomic status.
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to
estimate the relative risk for CL/P across the weight categories defined by BMI levels.
Multiple logistic regression analysis was used to adjust for differences in maternal
age, educational level of mother (college graduate, high school graduate only, and
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less than high school graduate), multivitamin use during the first trimester of
pregnancy, and history of smoking and alcohol use during the first trimester of
pregnancy (yes versus no for each) and model the effect of body weight on OFC risk.
Results
Among the case and control children, 58.6% (n=2,933) and 51.9% (n=5,480)
respectively were boys. Among the case children, cleft lip only (CLO) accounted for
22.8% (n=1,161), cleft palate only (CPO) 34.8% (n=1,774), and cleft lip with cleft
palate (CLP) accounted for 42.5% (n=2,162) of cases. Within CLO cases, 1,053 and
108 children cases were reported to have isolated and multiple birth defects,
respectively. 1,809 cases had isolated CLP and 353 cases had multiple CLP. Within
CPO cases, 1,313 and 461 CPO cases had isolated and multiple birth defects,
respectively.
Demographic characteristics of the sample appear in table 3-2. The mean ages
of mothers of cases and controls and the maternal BMI were not significantly
different at any site. Smoking during the index pregnancy period was common and
associated significantly with the risk of OFCs among Utah subjects (p-value=0.002),
Norway (p-value <0.001), and NBDPS studies (p-value <0.001). Use of alcohol by
the mother during the index pregnancy was significantly more frequent (pvalue=0.011) among the case versus control mothers in Norway study; no significant
associations were seen in the other studies. Maternal caffeine use during the first
trimester was associated significantly with the risk of OFCs in MoBa study only (pvalue=0.023). Maternal employment was significantly associated with the risk of
OFC in the Norway sample (p-value=0.019) and NBDPS sample (p-value=0.018), but
was not among any other study sites. Maternal folic acid intake was significantly
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associated with the risk of OFCs within Iowa (p-value=0.055) and NBDPS (pvalue=0.024) samples only. Maternal education was associated with the risk of OFC
within NBDPS sample (p-value <0.001).
The distribution of body weight categories varied considerably across study
sites. However, in subgroup analyses maternal body weight categories were only
significantly associated with the risk of OFCs within NBDPS sample group, where
higher percent of cases among underweight and obese mothers were observed (6.6%
and 20.6%) compared to controls (5.5% and 18.1%), respectively.
Logistic regression models were used to evaluate the association between
maternal BMI, maternal weight categories, and isolated and multiple OFCs combined
(CLO, CLP, CPO, and all clefts). In a multiple logistic regression analysis that
controlled for maternal age groups, maternal smoking during pregnancy, alcohol
drinking, multivitamin use, and education (college graduate, high school graduate,
and less than high school) shown in table 3-3, the estimated relative risk (adjusted OR
(aOR) and 95% confidence intervals (CIs)) for having cleft lip and cleft palate (CLP)
(aOR=1.15 [95%CI 1.00-1.32]), cleft palate with or without cleft lip (CP/L)
(aOR=1.13 [95%CI 1.01-1.25]), and all clefts combined (aOR=1.12 [95%CI 1.011.23]) increased significantly with maternal obesity. No effect of maternal obesity on
CLO was observed (aOR=1.06 [95%CI 0.89-1.27]). Associations between maternal
bodyweight categories and the risk of isolated clefts, including CLO, CLP, CPO,
CP/L, and all isolated cleft types combined were similar but were on the margins of
statistical significance.
Table 3-4 illustrates the risk of isolated OFCs by maternal BMI categories by
cleft types. Maternal body weight appeared not to be associated with any of the
isolated cleft types.
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Table 3-2. Demographic Characteristics of Mothers of Children with OFC Cases and Controls by Study Sites

Utah

Characteristics

Study Site
Norway-MoBa2

Iowa CC3

Total

NBDPS4
Cases

Controls

27.0 +5.7 26.8+5.2 28.9+5.0 29.23+4.8 29.9+5.0 30.0+4.6 26.7+5.3 27.1+4.9 26.9+6.2 26.9+6.1

27.2+6.0

27.2+5.9

29.4+6.4 28.9+5.6 28.9+5.0

31.8+5.5

32.9+6.0 32.9+5.6 26.7+5.3 27.1+4.9 30.0+6.9 29.8+6.8

29.9+7.0

29.9+6.8

24.3+5.0 24.2+5.3 23.7+4.4

23.4+3.7

23.9+4.2 24.1+4.2 23.5+5.2 23.0+4.4 25.3+6.2 25.0+5.8

24.9+5.8

24.8+5.5

Cases

Maternal age in years +
standard deviation (SD)
Paternal age in years + SD
Body-mass index (BMI;
kg/M2) + SD
Maternal BMI categories
Underweight5 %

Norway

CC1

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

6.6

6.8

3.3

3.7

5.0

4.4

6.3

8.0

6.7

5.5

6.3

5.4

55.3

59.5

3.3

3.7

63.6

62.6

65.4

65.4

49.1

51.4

53.4

54.3

25.3
12.8

21.5
12.1

19.5
8.1

18.8
7.0

19.0
12.4

23.1
9.9

19.7
8.7

17.6
9.0

23.6
20.7

25.1
18.1

23.0
17.3

24.0
16.2

Smoker %
Alcohol use in 1st trimester
%
Maternal employment %
Maternal caffeine use in 1st
trimester %
Multivitamin use %
Education < High School %

13.5

8

41.6

31.8

27.6

23.8

25.1

22.2

21.2

16.2

23.1

17.4

7.5

6.4

38.1

30.5

12.7

14

34.5

34.8

22.9

22.5

23.3

22.0

88.1

85.6

80.2

85.1

78.6

79.2

N/A

N/A

69.5

71.7

73.3

74.0

98.6

98.3

89.6

89.8

86.2

92.4

85.0

83.8

70.9

69.8

78.4

75.3

75.8
8.0

75.6
6.5

37.2
16.1

40.6
11.4

70.7
5.7

74.6
2.6

63.6
9.8

71.1
7.6

82.2
19.9

83.9
17.3

75.0
17.1

79.5
15.2

Education > College %
High School graduate %

26.7
65.2

30.5
63.0

39.6
44.2

40.9
47.7

62.7
31.6

62.4
34.9

18.1
72.1

22.5
69.9

26.0
54.2

31.6
51.1

28.3
54.6

33.4
51.4

Male %

59.2

60.6

60.3

53.3

58.2

55.2

53.8

54.0

58.6

50.9

58.6

51.9

Normal

Weight6

Overweight7
Obesity8

%

%

%

1Norway

case-control study.
mother-baby study.
3Iowa case-control study.
4National Birth Defect Prevention study.
5Underweight defined as BMI <18.5.
6 Normal weight defined as =>18.5, <25 BMI.
7Overweight defined as =>25, <30 BMI.
8Obesity defined as BMI=>30.
2Norway
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Table 3-3. Risk of Orofacial Clefts by Maternal Body Weight Categories and Cleft Types.
Maternal
Body Mass Index
(BMI2) Group
Underweight
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30
Obese
BMI >30

Adjusted odds ratios (aORs)3 and 95 percent confidence intervals (CIs) by Type of Clefts
Cleft Lip Only
1.05 [0.80-1.38]

Cleft Lip and Palate

Cleft Palate Only

Cleft Palate with or
without Cleft Lip

All Clefts

1.11 [0.90-1.36]

1.18 [0.95-1.48]

1.14 [0.97-1.34]

1.0 [Reference]

1.0 [Reference]

1.0 [Reference]

1.01 [0.92-1.10]

0.99 [0.88-1.12]

1.04 [0.91-1.18]

1.01 [0.92-1.11]

1.01 [0.92-1.10]

1.06 [0.89-1.27]

1.15 [1.00-1.32]

1.10 [0.95-1.27]

1.13 [1.01-1.25]

1.12 [1.01-1.23]

1.0 [Reference]

1.13 [0.97-1.31]
1.0 [Reference]

1Include

isolated orofacial clefts and those with multiple birth defects.
mass index, weight in kg/height in M2.
3Covariates in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol drinking,
multivitamin use, and education level.
2Body
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Table 3-4. Risk of Isolated Orofacial Clefts by Maternal Body Weight Categories by Cleft Types
Maternal
Body Mass Index
(BMI1) Group
Underweight
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30
Obese
BMI >30

Adjusted odds ratios (aORs)2 and 95 percent confidence intervals (CIs) by Cleft Types
Isolated Cleft Lip
Only
1.02 [0.76-1.37]
1.0 [Reference]

Isolated Cleft Lip
and Palate
1.11 [0.89-1.39]

Isolated Cleft Palate Isolated Cleft Palate All Isolated Clefts
Only
with or without Cleft
Lip
1.10 [0.85-1.43]
1.11 [0.93-1.34]
1.09 [0.93-1.29]

1.0 [Reference]

1.0 [Reference]

1.0 [Reference]

1.0 [Reference]

1.00 [0.85-1.18]

1.00 [0.87-1.13]

1.01 [0.87-1.17]

1.00 [0.90-1.11]

1.00 [0.91-1.10]

1.06 [0.88-1.28]

1.11 [0.96-1.29]

1.12 [0.94-1.32]

1.11 [0.99-1.25]

1.10 [0.99-1.23]

1Body

mass index, weight in kg/height in M2
in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol drinking,
multivitamin use, and education level.
2Covariates
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The association between OFC and maternal education level, shown in table 35, revealed that the risk of OFCs was significantly higher in mothers who were not
high school graduates compared to high school graduate mothers, with having college
graduate group as a reference. The risk in high school graduate only for CLP, CPO,
CP/L, and all cleft cases increased significantly (aORs of 1.36 [95% CI 1.20-1.54],
1.26 [95% CI 1.11-1.44], 1.32 [95% CI 1.20-1.45], and 1.24 [95%CI 1.14-1.35],
respectively).
Adjusted odds ratios by cleft type related to maternal body weight was
stratified by two levels of maternal education (less than college graduate versus
college graduate) (table 6). Because overweight seemed similar to normal weight in
that no effect on increased risk was observed, maternal overweight and normal weight
were combined in the reference group. This is also important because the data become
sparse when split into many subgroups. After controlling for maternal age, maternal
smoking during pregnancy, alcohol drinking, and multivitamin use, the risk of OFC
was higher for all body weight categories, including maternal underweight (aOR=1.23
[95% CI 1.02-1.49]), obesity among those with lower education levels (aOR=1.16
[1.03-1.31]). No significant associations were found with BMI among mothers who
were college graduates (table 3-6).
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Table 3-5. Risk of Orofacial Clefts1 by Maternal Education Level by Cleft Type
Adjusted odds ratios (aOR)2 and 95 percent confidence intervals (CI) by Cleft Types
Education Level
Cleft Lip Only
College graduate

1.0 [Reference]

High School graduate only
< High School graduate

Cleft Lip and Palate

Cleft Palate Only

Cleft Palate with or
without Cleft Lip
1.0 [Reference]

All Clefts

1.0 [Reference]

1.0 [Reference]

1.0 [Reference]

1.02 [0.87-1.19]

1.36 [1.20-1.54]

1.26 [1.11-1.44]

1.32 [1.20-1.45]

1.24 [1.14-1.35]

0.94 [0.72-1.22]

1.85 [1.52-2.25]

1.28 [1.02-1.59]

1.46 [1.23-1.73]

1.40 [1.21-1.62]

1Isolated

orofacial clefts and those with multiple birth defects
in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol use, multivitamin use, and
body weight categories.
2Covariates

81
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Adjusted odds ratios by cleft type were determined within each study site after
controlling maternal age, maternal smoking during pregnancy, alcohol drinking, and
multivitamin use, using CIs of 95% (table 3-7). In the Utah study, maternal
underweight appeared to be protective against the risk of having a child with CLO
(1.0 [reference]; aOR=0.16 [0.04-0.70]), while it appeared to increase the risk for all
CL (aOR=1.66 [95% CI 1.01-2.72]).
The total sample indicated a significant high risk for all cleft lip and all cleft
palate associated with maternal obesity (1.0 [reference]; aOR=1.13 [95% CI 1.001.26]) and 1.13 [1.01-1.25]). Other maternal categories did not show any effect on the
risk of cleft.
Table 3-6. Adjusted1 Odds Ratio (aORs) and 95% Confidence Intervals (CI) of
Cleft Palate, with or Without cleft lip, Isolated or With Multiple Birth Defects By
Maternal Body Mass Index (BMI)2 Group, Stratified by Two Levels of Maternal
Education.
Adjusted odds ratios (aOR) and 95 percent confidence intervals (CI) by Cleft
Types
Maternal level
of education

< College
Graduate

College
Graduate

1Covariates

Maternal BMI

Cleft Palate with or without
Cleft Lip

Underweight
BMI <18.5

1.23 [1.02-1.49]

Normal Weight BMI >18.5, < 25; and
Overweight BMI >25, <30

1.00 [reference]

Obese
BMI >30

1.16 [1.03-1.31]

Underweight
BMI <18.5

0.85 [0.59-1.23]

Normal Weight BMI >18.5, < 25; and
Overweight BMI >25, <30

1.00 [reference]

Obese
BMI >30

1.00 [0.79-1.27]

in multiple logistic regression models include study site, maternal age, maternal
smoking during pregnancy, alcohol use, and multivitamin use.
2Body mass index, weight in kg/height in M.2
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Table 3-7. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals (CIs) of Isolated and Multiple OFCs Combined by maternal
Body Mass Index group by cleft type and study site
Study site

Utah

Norway CC

MoBa

Iowa CC

Maternal Body Weight
Category

Cleft lip only
0.16 [0.04-0.70]
1.00 [reference]

All Cleft palate2
1.13 [0.68-1.86]
1.00 [reference]

All Cleft Lip
0.56 [0.30-1.04]

All Clefts
0.85 [0.52-1.37]

1.00 [reference]

1.00 [reference]

1.03 [0.65-1.63]

1.12 [0.82-1.52]

1.15 [0.84-1.58]

1.09 [0.82-1.46]

1.06 [0.61-1.85]

1.19 [0.81-1.76]

1.13 [0.76-1.69]

1.16 [0.81-1.66]

0.66 [0.22-2.00]

1.28 [0.70-2.34]

0.95 [0.49-1.86]

1.11 [0.63-1.97]

1.00 [reference]

1.00 [reference]

1.00 [reference]

1.00 [reference]

1.10 [0.67-1.80]

1.16 [0.85-1.58]

0.99 [0.70-1.38]

1.13 [0.85-1.50]

1.85 [0.95-3.60]

1.14 [0.72-1.83]

1.42 [0.89-2.25]

1.26 [0.82-1.92]

0.00

0.52 [0.17-1.59]

0.32 [0.07-1.45]

0.46 [0.15-1.41]

1.00 [reference]

1.00 [reference]

1.00 [reference]

1.00 [reference]

0.729 [0.26-2.61]

0.73 [0.42-1.27]

0.88 [0.49-1.59]

0.74 [0.44-1.25]

0.30 [0.04-2.47]

1.07 [0.56-2.06]

0.687 [0.30-1.56]

0.96 [0.51-1.80]

1.15 [0.40-3.28]

1.05 [0.53-2.05]

0.99 [0.46-2.11]

1.09 [0.59-2.03]

1.00 [reference]

1.00 [reference]

1.66 [1.01-2.72]

1.35 [0.88-2.07]

1.00 [reference]
1.46 [0.67-3.185]

1.00 [reference]
1.34 [0.85-2.08]

Continued
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Underweight
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30
Obese
BMI >30
Underweight
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30
Obese
BMI >30
Underweight
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30
Obese
BMI >30
Underweight
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30

Adjusted odds ratios by cleft type
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Study site

Maternal Body Weight
Category

Obese
BMI >30
Underweight
NBDPS
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30
Obese
BMI >30
Underweight
Total sample BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30
Obese
BMI >30

Adjusted odds ratios by cleft type
Cleft lip only
0.892 [0.24-3.31]

All Cleft palate2
1.09 [0.58-2.04]

All Cleft Lip
1.38 [0.69-2.74]

All Clefts
1.02 [0.56-1.88]

1.27 [0.94-1.74]

1.16 [0.96-1.41]

1.23 [1.01-1.51]

1.19 [0.99-1.41]

1.00 [reference]

1.00 [reference]

1.00 [reference]

1.00 [reference]

0.98 [0.81-1.18]

0.99 [0.88-1.11]

0.96 [0.85-1.08]

0.99 [0.89-1.09]

1.05 [0.85-1.29]

1.15 [1.02-1.30]

1.12 [0.99-1.28]

1.13 [1.01-1.27]

1.05 [0.80-1.38]

1.14 [0.97-1.34]

1.10 [0.92-1.31]

1.13 [0.97-1.31]

1.00 [reference]

1.00 [reference]

1.00 [reference]

1.00 [reference]

1.01 [0.92-1.10]

1.01 [0.92-1.11]

0.99 [0.90-1.10]

1.01 [0.92-1.10]

1.06 [0.89-1.27]

1.13 [1.01-1.25]

1.13 [1.00-1.26]

1.12 [1.01-1.23]

1Covariates

in multiple logistic regression models include study site, maternal age, maternal smoking during pregnancy, alcohol use, maternal education (3levels), and multivitamin use.
2 Cleft palate with or without cleft lip.
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Discussion
Statement of Principal Findings
This study provides evidence that maternal obesity increases the risk of having
a child with a cleft palate with or without cleft lip (CP/L). Maternal underweight
appears to increase the risk of CP/L in the offspring. The association between low
level of maternal education level and increased risk of CLP, CPO, CP/L, and all clefts
was significant, while among mothers with higher education, underweight and obese
were not associated with an elevated risk for orofacial clefts (OFCs).
Strengths of the Study
The current study has several strengths. It represents the largest international
consortium of case-control study to date with multiple countrywide sites in Europe
and statewide sites in the US. The study is population-based and relatively robust
against selection bias. OFC cases were drawn from birth defects registries. Controls
were randomly selected from centralized birth records. Data obtained from the birth
defect registries and birth records are rich data sources with respect to information on
potential confounders. However, information on potential confounders were collected
from participants’ interview. The study was designed to use well-defined procedures
for case definition and careful classification of OFCs and associated conditions by
clinical specialists.
In some studies, conclusions about the association between maternal obesity
and orofacial clefting were limited by small number of cases 5, 9, 12, 24. The present
study was designed to test maternal weight hypotheses in relation to OFCs. High
quality data were available on several relevant covariates to control for potential
confounding. Statistical analyses were conducted for both isolated and non-isolated
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clefts combined and cleft type. The effects of maternal underweight, overweight, and
obesity on the risk of orofacial cleft were all evaluated. As obesity is an epidemic
health problem, a modest effect of maternal obesity can be linked to a significant
burden of OFCs. Maternal underweight is associated with several adverse outcomes.
Nevertheless, it remains an understudied problem. Results of this study confirmed that
maternal obesity increases the risk of having a child with a CLP, CP/L, and all OFC
types combined, while no effect of obesity on CLO was observed. Maternal
underweight appeared to increase the risk of CP/L in the offspring. The association
between low level of maternal education level and the risk of all OFC types was
significant, while among mothers with higher education, underweight and obesity
were not associated with risk of OFCs.
Limitations of the Study
Potential limitations of this study include the use of self-reported prepregnancy weight and height and the possibility of recall bias among underweight and
obese women 25. Data on exposures to smoking, multivitamin intake and
socioeconomic status were limited to dichotomous exposure levels, thus residual
confounding related to these factors is a possibility. As in all case-control studies,
recall bias is a concern. Additionally, weight association with orofacial clefts was
modified by the socioeconomic status as indicated by mother’s level of education,
which is a limited measure of socioeconomic status.
Strength and Weaknesses in Relation to Other Studies
With the rising rates of excess weight among pregnant women 26, the current
findings of an association between maternal obesity and OFCs in the offspring is a
major public health concern. Studies of the association between pre-pregnancy
maternal weight and risk of OFCs have produced inconsistent findings that may be
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related to variations in population sample size, definitions of OFC subtypes, lack of
consideration of maternal underweight, and inadequate control of potential
confounding factors.
In the present study, a positive association was found between both maternal
underweight and obesity in early pregnancy and isolated and multiple OFC groups
combined in the offspring. Similarly, Waller et al. reported that mothers who were
underweight had no significant increase or decrease in the risk for birth defects,
except for a significant increase in risk for cleft lip with or without cleft palate
(aOR=1.35 [95% CI 1.04-1.76] 11. A meta–analysis conducted to assess current
evidence of the association between maternal overweight, maternal obesity, and
congenital anomaly also reported increased risks for CP (aOR=1.23 [95% CI 1.031.47]) and CLP (aOR=1.20 [95% CI 1.03-1.40]) 6. Rankin et al. (2010) found an
overall increased risk of congenital anomalies in women who were obese and
underweight compared with women of recommended weight, but no association
between maternal underweight and OFCs was found, OR=1.84 [95% CI 0.55–6.25].
This study included only 44 infants with OFCs 27.
The association of obesity with clefts has been observed in a few other studies,
although low numbers of cases limited their statistical power 5, 27, 28. Cedergren and
Kallen (28) observed modest increases in the risk of CP and CL/P associated with
pre-pregnancy BMI of >29, while another case-control study reported an increase in
the birth prevalence of all OFCs among women with BMI of ≥ 30 as compared with
those with a BMI of < 30, OR=1.7 [95% CI 1.1-2.8] 9. Oddy et al. found twofold
increased odds of having infants with OFCs in mothers with a BMI of ≥ 30,
aOR=1.97 [95% CI 0.73-5.32], where only 6 mothers out of 48 were classified as
obese 24. Recently, a population-based case-control study conducted in Florida found
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obese women to experience increased odds of having a child with CL/P after
controlling for maternal race, education, smoking, marital status, nativity, and
maternal age (OR=1.25 [95% CI 1.05-1.48] and CP, OR=1.32 [1.07-1.62]). However,
in this same study, the offspring of underweight mothers were not at a higher risk of
OFCs 29. One limitation of their study is the lack of information on intake of vitamin
supplement, which might have confounded the associations between pre-pregnancy
maternal underweight/obesity and clefts.
Similar to our findings, there was a strong association between CP/L and
obesity but not with CLO 11. We also found a significant positive association when we
combined CP with CL and all cleft palate. A previous study indicated a possible effect
of maternal obesity on cleft palate malformation through the indirect influence of
excess adiposity related to the bioaccumulation and release of dioxins, causing cleft
palate in mice 30. Thus, our results suggest the associations with maternal bodyweight
are specific to cleft palate and not to cleft lip.
A case-control study reported an increased risk of isolated and multiple birth
defects by maternal GDM in the presence of maternal obesity after adjusting for
potential confounders 31. Marengo et al. reported a positive association between BMI
and CPO among non-diabetic mothers (p< 0.05). For cleft lip, however, the
prevalence was statistically elevated only among the non-diabetic mothers with class3 obesity (BMI ≥40), aOR=1.55 [95 % CI 1.14 -2.07]. Authors of this study found
that smoking and education were not confounders of the association between BMI
and birth defects. Therefore, they adjusted for maternal race/ethnicity and maternal
age only 32 . In addition, the percentage of obese mothers reported in their sample was
22.70%, but the prevalence of obesity within mothers of OFC cases was not
described. Stott-Miller et al. reported a very modest elevation in risk of OFCs in
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relation to maternal obesity. This could be due to residual confounding related to data
collection, imprecision of primary exposure that may have biased the results, and/or
the considerable amount of missing data for maternal BMI and pre-pregnancy weight
8

.
Elevated risks for OFCs with increasing BMI were not observed in some other

studies. Shaw et al. (2000) reported insignificant ORs for the risk isolated CL/P,
aOR=1.0 [95% CI 0.6-1.6]; isolated CP, aOR=1.1 [0.6-2.0]; multiple CL/P, aOR=1.0
[ 0.5-2.1]; and multiple CP, aOR=1.6 [0.8-3.4] 33. However, there were too few cases
with maternal pre-pregnancy obesity studies to obtain valid adjusted estimates of the
ORs. Villamor et al. (2008) evaluated the risk of OFCs in relation to pre-pregnancy
weight change and interpregnancy interval. Data revealed an increased risk of isolated
CP 2.3 times [95% CI 1.4-4.0] within women whose second-pregnancy BMI was ≥ 3
units higher than their first-pregnancy BMI as compared with women whose BMI did
not change significantly, while the BMI change was not related to the risk of cleft lip
10

.

Implications for Clinicians and Policymakers
What mechanisms could link maternal underweight and obesity to OFCs in the
offspring? Whatever the underlying mechanism behind the observed associations is,
maternal underweight and obesity appear to increase the risk for CP/L malformations
but only in the less educated mothers. It is possible that the educated mothers have the
characteristic of being “obese but metabolically healthy” or “underweight but
metabolically healthy.” These terms describe a subset of people who seem to be
protected against obesity- and underweight-related metabolic complications 34-39. As
the association between maternal bodyweight and the risk of CP/L was significant,
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while no association with CLO existed, further investigation may yield insight into
lip-palate-specific mechanisms of development.
A possible explanation for the association between maternal obesity and OFCs
is undetected type-2 diabetes with hyperglycemia and insulin resistance. A previous
study reported that even in the absence of gestational diabetes, obese women were
found to have an impaired glucose metabolism 40, which may be associated with an
elevated risk for OFCs 5, 41, 42. Another possibility is that cases involved in the current
study included “obese but metabolically healthy” or “underweight but metabolically
unhealthy” individuals. These terms describe a subset of people who seem to be
protected against obesity-related metabolic complications and individuals who are
underweight but, like people with overt obesity, are insulin resistant and predisposed
to type-2 diabetes and hypertriglyceridemia, respectively. Maternal body size, both
underweight and obesity, appears to be an indirect measure of cleft risk. Up to onethird of obese persons are “metabolically healthy” 34-39 and this state of “metabolically
healthy obesity” was correlated with higher educational status in the present study.
Likewise, a substantial proportion of underweight persons might be “metabolically
unhealthy.”
Another possible explanation for the association between maternal obesity and
OFCs could be improper nutrition. Shaw et al. (1995) and Itikala et al. (2001)
suggested a possible role of folic acid deficiency on increasing the risk for OFCs 43, 44,
while other studies reported inconsistent findings 45, 46. Additionally, high dietary
glycemic load intake was found to be more common among mothers of OFC cases 47,
48

. Hendricks et al. (2001) have suggested a possible role of maternal poor glycemic

control, independent of diabetes diagnosis, on the risk of OFCs 49. Previous findings
provide evidence for higher levels of insulin resistance among obese patients 50-52.
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Thus, the joint effect of abnormal glucose metabolism and obesity provide evidence
of a synergistic effect on the risk of OFCs. Although the development of facial
structure occurs within the first trimester of pregnancy, there are only a few data on
glucose screening tests before 24 weeks of gestation. Further studies on appropriate
methods for diabetes testing in early pregnancy are recommended.
Our results also revealed significant associations between maternal education
levels and the risk of CLP and all cleft palates, with a significant higher risk in CLP
and all cleft cases, while Cedergren & Kallen 28 produced inconsistint finding of a
weak association between maternal education levels, and maternal obesity and infant
clefts. This may relate to the limited number of subjects with a known BMI in their
study. However, authors suggested a possible indirect association through the effect
of maternal obesity at low maternal education.
Conclusions
Maternal underweight and obesity are significantly associated with the risk of
CPs but not CLO. The metabolic abnormalities underlying the increased risk are
unknown and require further study. Surprisingly, a strong modification of the
association was found by maternal education. It is possible that the BMI is just an
indirect measure for the risk and college educated mothers who are obese are more fit
and metabolically healthy than obese mothers with lower education levels. A more
detailed assessment of socioeconomic status is needed. In addition, our findings
highlight the need to assess the obese mothers for hyperglycemia early in pregnancy
to reduce the risk of OFCs in their offspring.
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CHAPTER 4
THE ROLE OF GESTATIONAL DIABETES MELLITUS AND
HYPERTENSION ON THE RISK OF OROFACIAL CLEFTS IN UTAH 1
Abstract
Objective: To evaluate whether maternal gestational diabetes mellitus (GDM) and
hypertension are independently associated with risk of orofacial clefts.
Methods: A statewide case-control study of clefts in Utah during 1995 to 2004, in
collaboration with the Utah Birth Defects Network (UBDN) involved mothers of 562
infants with cleft, in which 430 cases were classified as isolated cleft cases and 133 as
all multiples, syndromic, or chromosomal clefts, matched with 658 controls randomly
selected unaffected births (from birth certificates) matched to cases by month, year of
birth, and gender of the child. Descriptive analysis was conducted in SPSS to examine
the association between GDM, hypertension, and orofacial clefts (OFCs). Odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated to estimate the relative risk
for cleft lip with or without cleft palate (CL/P), cleft palate only (CPO), and all clefts
(isolated and non-isolated clefts combined) according to the presence of diabetes or
hypertension. Adjusted ORs (aORs) include control for potential confounding due to
factors such as maternal smoking, periconceptional multivitamin use, maternal
education level, body-mass-index (BMI), and maternal age.
Results: Maternal GDM was significantly associated with isolated clefts (aOR=2.63
[CI 95% 1.30-5.34]) and non-isolated clefts (aOR=2.66 [95% CI 1.015-6.97]).
Maternal hypertension was significantly associated with non-isolated clefts
(aOR=6.56 [95% CI 2.12-19.77]) and results were suggestive for isolated clefts
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(aOR=2.56 [95% CI 0.91-7.15]). We found a further increased risk of OFCs among
GDM vs. non-GDM mothers who were obese (Body Mass Index (BMI>30) for
isolated clefts (aOR=4.96 [1.26-19.51]) and for non-isolated clefts (aOR=14.21 [2.5280.21]). Mothers with hypertension who were also obese had an elevated risk for nonisolated OFCs only (aOR=29.88 [95% CI 2.45-363.83]).
Conclusions: Both GDM and hypertension were associated with OFCs, suggesting a
possible existence of underlying abnormalities related to metabolic syndrome prior to
pregnancy. Screening for diabetes and hypertension earlier in the periconceptional
period may be needed to reduce the risk of OFCs in the offspring.
Introduction
Maternal diabetes mellitus (DM) 1-3 and hypertension 4, 5 have been implicated
in several studies as possible etiological factors of various infant congenital
malformations. Orofacial clefts (OFCs) are among the most frequent congenital birth
defects in human 6. However, further studies are needed for a more complete
understanding of the etiology of this disorder 7.
Diabetes mellitus is a group of metabolic diseases results from defects in
insulin secretion, insulin action, or both and characterized by chronic hyperglycemia
with disturbances of carbohydrate, fat and protein metabolism. Three main types of
diabetes have been defined: type-1, type-2, and gestational diabetes 8. Type-1 diabetes
mellitus or insulin-dependent diabetes mellitus (IDDM) is partly inherited and then
triggered by certain infections. It results from a T-cell mediated autoimmune
destruction of the pancreatic beta cells in genetically predisposed individuals 9. Type2 diabetes or non-insulin-dependent diabetes mellitus (NIDDM) is due primarily to
lifestyle factors and genetics 10. Type 1 and 2 are both conditions that can be treated
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but not cured. Hence, diet, exercise, and use of appropriate medications to keep blood
sugar levels as close to normal "euglycemia" can be achieved 11. Since 1970,
Navarrete et al. indicated a definitive relation between a maternal glucose metabolic
disorder and congenital malformations and suggested research into the early phases of
diabetic state in mothers of malformed infants 12.
Gestational diabetes mellitus (GDM) is a condition in which women without
previously diagnosed diabetes exhibit high blood glucose levels (particularly during
third trimester of pregnancy) when their bodies do not secrete excess insulin required
during pregnancy 13. However, women with GDM are at high risk for having or
developing diabetes when they are not pregnant 14. It has been predicted that women
who develop GDM later in pregnancy may also have had undetected metabolic
problems earlier in the pregnancy 15.
Hypertension is a chronic medical condition in which the systemic arterial
blood pressure is elevated, increasing the blood pressure to a level that induces some
adverse effects such as the cardiovascular damage. Normal blood pressure is
120/80 mmHg, while high blood pressure is anything more than 140/90 mmHg 16. A
case-control study conducted in Thailand sought to identify the risk factors for
congenital malformations from May 1987 to April 1988. Cleft lip or cleft palate was
among one of the most common types of malformations. Maternal age >35 years, low
maternal education levels, separated/divorced marital status, family history of similar
anomalies, an accident during pregnancy, maternal illness during pregnancy, and
maternal hypertension during pregnancy were significantly associated with the risk of
orofacial clefts (OFCs) 4.
There is a substantial overlap between diabetes and hypertension, reflecting
substantial overlap in their etiology and mechanisms. Among all diabetics,
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hypertension is found in over 70% 17. Common pathways shared by DM and
hypertension include Sympathetic Nervous System, Renin-Angiotensin-Aldosterone
System, oxidative stress, adipokines, and insulin resistance (Fig. 4-1). These pathways
may interact and influence each other.
Abdominal obesity, aberrant glycemic control, hyperlipidemia, or
hypertension is variably defined as co-occurrence of metabolic syndrome 18. Mothers
who develop GDM later in pregnancy may have had undiagnosed type-2 DM and are
susceptible to acquire DM later in life 15. Some of the common co-morbidities of
GDM include increased oxidative stress and inflammation and immune dysfunction
19

. Investigation of metabolic syndrome, with the presence of diabetes, hypertension,

and other more serious physiologic consequences, may provide useful clues regarding
birth defects associations 20. We assessed the relationship between maternal
gestational diabetes and hypertension and the risk of OFC. These two risk factors are
hypothesized to cause cleft lip and cleft palate via metabolic abnormalities that affect
fetal development. This set of related hypotheses was examined in analyses of data
from the Utah cleft study.
Materials and Methods
A statewide case-control study of clefts was conducted in Utah during 1995 to
2004 in collaboration with the Utah Birth Defects Network (UBDN). The UBDN staff
members attempted to contact potential case and control mothers by mail to obtain
consent for release of their names to USU investigators. Address updates were sought
using available Internet services. If no mailing address was available, attempts were
made to locate the mothers in person by field tracing that included visits to the last
known home address and inquiries with neighbors. Interviews with mothers were
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Figure 4-1. Summary of Putative Pathophysiologic Mechanisms in the
Development of Hypertension in Diabetes Mellitus. RAAS_Renin- AngiotensinAldosterone System; SNS_Sympathetic Nervous System; VSMC_Vascular Smooth
Muscle Cell 21.
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conducted primarily by telephone; however, personal interviews were completed if no
telephone was available. The interview included questions on demographic
characteristics of the biologic parents, a reproductive health and pregnancy history,
supplement use, medications, medical conditions, and smoking and alcohol use. Each
mother received an individualized, color-coded pregnancy calendar that was
generated based on the date of delivery of her index child and the self-reported
gestational length. This visual aid was intended to assist mothers in recalling activities
and timing of events during various periods referred to. Color-coding of the calendars
indicated the reference periods including the 3-month period before the estimated date
of conception and three trimesters. Interview materials were translated into Spanish,
and a bilingual interviewer contacted mothers speaking Spanish only. The UBDN
later joined the National Birth Defects Prevention Study (NBDPS). A detailed
description of data collection is provided elsewhere 22.
Combined samples involved 375 cases with cleft lip with or without cleft
palate (CL/P), 187 cases with cleft palate only (CPO), and 658 randomly selected
unaffected births matched cases by month, year of birth, and gender of the child. Data
were available on pre-pregnancy maternal weight and height and other perinatal and
demographic factors, which were used as covariates to control for potential
confounding. Body-mass-index (BMI) was computed as weight kilograms
(kgs)/height (m2) and used to define body weight categories as underweight
(BMI<18.5 kg/ m2), normal weight (18.5- <25 kg/ m2), overweight (25-<30 kg/ m2)
and obese (≥30 kg/ m2).
SPSS statistical analysis version 20.0 was used to describe the characteristics
of study population. Descriptive analysis was conducted in SPSS to examine the
association between maternal GDM and hypertension and other factors, such as
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maternal age, history of smoking (three months prior to conception), multivitamin use
during the first trimester of pregnancy, and education level (college graduate, high
school graduate only, and less than high school graduate) and alcohol consumption.
Simple Chi-square analysis of contingency tables for categorical analysis was
used to examine the association between each independent variable and selected
covariates, such as maternal educational level, multivitamin (MVI) use during the first
trimester of pregnancy, smoking, and alcohol consumption.
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to
estimate the relative risk for CLO, CL/P, and all OFCs according to the presence of
diabetes and hypertension. Multiple logistic regression analysis was used to adjust for
differences in maternal age, multivitamin use, and history of smoking and model the
effect of diabetes and hypertension on CPO, CL/P, and all OFC risk.
Results
Table 4-1 shows the demographic characteristics of study participants. Among
the case and control children, 60.3% (n=339) and 60.9% (n=401) respectively were
boys. Among the case children, CL/P accounted for 66.7% (n=375) and CPO
accounted for 33.3% (n=187) of cases. Maternal age, mean BMI, and alcohol drinking
three months prior to pregnancy were not significantly different between mothers of
cases and controls. Maternal smoking three months prior to pregnancy was
significantly higher among mothers of cases (15.5%; n=85) than controls (10.0%;
n=64). Maternal use of MVI was not statistically different between cases (33.8%;
n=186) and controls (29.9%; n=192). Maternal education was significantly different
among mothers of cases and controls (p-value=0.017), with a higher percent of
mothers of controls holding a college degree (31.1%; n=200) or completed some
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college (44.2%; n=248) compared to mothers of cases (27.5%; n=151 and 40.4%;
n=222), respectively. Mothers of cases were more frequent to be high school graduate
or less (32.2%; n=177) compared to mothers of controls (24.7%; n=159).
The prevalence of maternal GDM and hypertension was significantly higher
(p-value=0.004) among mothers of cases (5.2%; n=29 and 3.20%; n=18) than controls
(2.1%; n=14 and 0.9%; n=6), respectively. GDM was also associated with the higher
BMI value (p-value=0.004), but not with older maternal age (p-value=0.134).
Maternal hypertension, however, was not significantly associated with maternal BMI
at conception (p-value=0.088), while appeared more frequent among mothers with
older age (p-value=0.042). Maternal GDM and hypertension were not associated with
maternal smoking (p-value=0.383 and 0.459), MVI use (p-value=0.941 and 0.321), or
education level (p-value=0.752 and 0.677), respectively.
Table 4-2 illustrates the crude and adjusted Odds Ratios (aORs) for GDM on
isolated, non-isolated OFC subtypes and both types combined. GDM appears to
increase the risk for isolated CPO (aOR=3.36 [95% CI 1.28-8.81]), CL/P (aOR=2.49
[95% CI 1.15-5.36]), and all isolated clefts (aOR=2.63 [95% CI 1.30-5.34]); nonisolated CPO (aOR=3.65 [1.12-11.86]) and all non-isolated OFC (aOR=2.66 [1.026.97]), but not for non-isolated CL/P (aOR=2.12 [0.57-7.87]). Overall, GDM
increased the risk for isolated and non-isolated CPO (aOR=3.42 [95% CI 1.48-7.91]),
CL/P (aOR=2.33 [95% CI 1.11-4.87]), and all OFCs (aOR=2.58 [95% CI 1.31-5.06]).
Table 4-3 illustrates the crude and aORs for maternal hypertension on isolated,
non-isolated, and both isolated and non-isolated OFC types and subtypes. Maternal
hypertension increases the risk for non-isolated CPO (aOR=5.76 [95% CI 1.3524.59]), CL/P (aOR=7.87 [95% CI 2.21-27.94]), and all non-isolated OFCs
(aOR=6.56 [95% CI 2.18-19.77]); and all CPO (aOR=3.78 [95% CI 1.18-12.07]),
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Table 4-1. Demographic Characteristics of Orofacial Cleft Cases and Controls; Utah Child and Family Health Study
Characteristics

Controls
(n=658)

CL/P
(n=375)

Cases
CPO
(n=187)

All Clefts
(n=562)

Mean Maternal Age + standard deviation (SD)

26.2+ (5.3)

26.3+ (5.3)

26.8+ (5.9)

26.5 + (5.7)

Mean BMI+ (SD)

24.3+ (5.4)

25.2+ (11.7)

25.1+ (12.9)

25.1+ (12.1)

Pre-existing Diabetes (%)

2 (0.3)

1 (0.3)

0 (0.0)

1 (0.2)

Gestational Diabetes Mellitus (%)

14 (2.1)

18 (4.8)

11 (5.9)

29 (5.2)

Hypertension (%)

6 (0.9)

12 (3.2)

6 (3.2)

18 (3.20)

Gestational Diabetes Mellitus and Hypertension Combined (%)

1 (0.2)

4 (1.1)

2 (1.1)

6 (1.1)

Average month of Diagnosis of GDM + (SD)

6.2+ (1.2)

5.3+ (1.8)

5.7 + (2.0)

5.4 + (1.8)

Maternal Smoking 3-Months Prior to Pregnancy (%)

64 (10.0)

58 (15.7)

27 (15.0)

85 (15.5)

Maternal Alcohol Consumption 3-Months Prior to Pregnancy (%)

145 (22.6)

100 (27.0)

40 (22.2)

140 (25.5)

Supplement use during first trimester of pregnancy (%)

192 (29.9)

118 (31.9)

68 (37.8)

186 (33.8)

College Graduate (%)

200 (31.1)

92 (24.9)

59 (32.8)

151 (27.5)

Male Cleft Cases (%)

401 (60.9)

244 (65.1)

95 (50.8)

339 (60.3)
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Table 4-2. Risk of Orofacial Clefts by Maternal Gestational Diabetes Mellitus by
Cleft Types
Cleft Group

Odds Ratios and 95% Confidence Intervals by Cleft Subtype
CL/P1

CPO2

CL/P and CPO

Crude

2.36 [1.13-4.96]

2.78 [1.10-7.03]

2.48 [1.26-4.90]

Adjusted3

2.49 [1.15-5.36]

3.36 [1.28-8.81]

2.63 [1.30-5.34]

Crude

2.12 [0.60-7.58]

3.07 [0.98-9.61]

2.56 [1.01-6.46]

Adjusted3

2.12 [0.57-7.87]

3.65 [1.12-11.86]

2.66 [1.02-6.97]

Isolated and

Crude

2.32 [1.14-4.72]

2.88 [1.28-6.44]

2.50 [1.31-4.79]

Non-Isolated

Adjusted3

2.33 [1.11-4.87]

3.42 [1.48-7.91]

2.58 [1.31-5.06]

Isolated

Non-Isolated

Cleft lip, with or without cleft palate; n=15 (4.9%) isolated, 3 (4.4%) non-isolated.
Cleft palate only; n= 7 (5.7%) isolated, 4 (6.3%) non-isolated.
3 Covariate in logistic regression model include maternal age, body-mass-index, education,
multivitamin use, and smoking.
1
2

CL/P (aOR=3.50 [95% CI 1.28-9.55]), and all OFCs (aOR=3.42 [95% CI 1.34-8.74]).
However, no effect for maternal hypertension on isolated OFCs was observed. Crude
and adjusted ORs of Maternal GDM by maternal body weight categories (normal
weight, overweight, and obesity) for isolated, non-isolated, and all clefts appear in
table 4-4. Underweight category was skipped, as no participants appeared to be
underweight with GDM. The aORs of GDM imply the increased risk for isolated
(aOR=4.96 [1.26-19.51]), non-isolated (aOR=14.21 [2.52-80.21]), and all clefts
(aOR=6.30 [1.71-23.21]) among obese mothers only.
Crude and adjusted ORs of Maternal hypertension by maternal body weight
categories (normal weight, overweight, and obesity) for isolated, non-isolated, and all
clefts appear in table 4-5. Maternal hypertension increases the risk for non-isolated
OFCs among obese mothers only (aOR=29.88 [2.45-363.83]).
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Table 4-3. Risk of Orofacial Clefts by Maternal Hypertension by Cleft Types
Odds Ratios and 95% Confidence Intervals by Cleft Subtype
Cleft Group

CL/P1

CPO2

CL/P and CPO

Crude

2.54 [0.85-7.61]

2.71 [0.67-10.98]

2.59 [0.93-7.17]

Adjusted3

2.54 [0.84-7.73]

2.82 [0.68-11.69]

2.56 [0.91-7.15]

Crude

8.60 [2.55-28.97]

5.33 [1.30-21.83]

6.93 [2.37-20.33]

Adjusted3

7.87 [2.21-27.94]

5.76 [1.35-24.59]

6.56 [2.18-19.77]

Isolated and

Crude

3.59 [1.34-9.65]

3.59 [1.14-11.27]

3.59 [1.42-9.11]

Non-Isolated

Adjusted3

3.50 [1.28-9.55]

3.78 [1.18-12.07]

3.42 [1.34-8.74]

Isolated

Non-Isolated

Cleft lip, with or without cleft palate; n=7 (2.3) isolated, 5 (7.4%) non-isolated.
Cleft palate only; n= 3 (2.4%) isolated, 3 (4.7%).
3 Covariate in logistic regression model include maternal age, body-mass-index, education,
multivitamin use, and smoking.
1
2

Table 4-4. Risk of Orofacial Clefts by Maternal Gestational Diabetes Mellitus by
Cleft Types Stratified by Maternal Body-Mass-Index (BMI) Categories
Maternal BMI

Odds Ratios and 95% Confidence Intervals by Cleft Type

Group1
Normal weight2

Overweight3

Obesity4

1Data

Isolated Clefts

Non-Isolated Clefts

All Clefts

n=430

n=133

n=562

Crude

1.64 [0.57-4.73]

0.71 [0.09-5.84]

1.41 [0.51-3.94]

Adjusted5

1.78 [0.57-5.53]

0.72 [0.08-6.52]

1.46 [0.48-4.39]

Crude

1.31 [0.32-5.37]

1.69 [0.18-15.87]

1.37 [0.36-5.23]

Adjusted5

1.38 [0.32-5.93]

1.73 [0.17-17.61]

1.36 [0.34-5.36]

Crude

5.73 [1.50-21.87]

8.78 [1.89-40.70]

6.48 [1.79-23.38]

Adjusted5

4.96 [1.26-19.51]

14.21 [2.52-80.21]

6.30 [1.71-23.21]

for underweight mothers not included as it was too sparse for analysis.
>18.5, < 25; n=7 isolated, 1 non-isolated clefts.
3BMI >25, <30; n=4 isolated, 1 non-isolated clefts.
4BMI >30; n=10 isolated, 5 non-isolated clefts.
5Covariates in logistic regression model include maternal age, body-mass-index, education,
multivitamin use, and smoking.
2 BMI
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Table 4-5. Risk of Orofacial Clefts by Maternal Hypertension by Cleft Types
Stratified by Maternal Body Weight Categories
Maternal BMI
Group1

Odds Ratios
(ORs)

Odds Ratios and 95% Confidence Intervals by Cleft Type
Isolated Clefts
n=430

Normal
weight2

Overweight3

Obesity4

Non-Isolated Clefts
n=133

All Clefts
n=562

Crude

4.11 [0.79-21.34]

2.51 [0.23-27.97]

3.73 [0.75-18.58]

Adjusted5

4.16 [0.78-22.04]

2.24 [0.19-25.80]

3.63 [0.72-18.37]

Crude

0.86 [0.14-5.26]

4.77 [0.75-30.42]

1.462 [0.32-6.66]

Adjusted5

0.81 [0.13-5.19]

5.11 [0.66-39.64]

1.41 [0.29-6.88]

Crude

4.53 [0.46-44.70]

20.00 [2.10-190.91]

8.12 [0.97-67.61]

Adjusted5

3.56 [0.35-36.66]

29.88 [2.45-363.83]

6.99 [0.81-60.27]

1Data

for underweight mothers not included as it was too sparse for analysis.
>18.5, < 25; n=5 isolated, 1 non-isolated clefts.
2BMI >25, <30; n=2 isolated, 2 non-isolated clefts.
3BMI >30; n=3 isolated, 4 non-isolated clefts.
4Covariates in logistic regression model include maternal age, body-mass-index, education,
multivitamin use, and smoking.
1 BMI

Discussion
This study provides evidence that maternal GDM increases the risk of having
a child with isolated CPO, CL/P, and all isolated clefts; all CPO, CL/P, and all clefts;
and non-isolated CPO and all non-isolated OFCs significantly. Maternal hypertension
increases the risk for non-isolated and all CPO, CL/P, and all non-isolated and all
OFCs significantly, but not for isolated OFCs.
An association between maternal GDM by obesity and increased risk of
isolated, multiple, and isolated and multiple clefts combined found to be statistically
significant, while maternal hypertension by obesity increases the risk for non-isolated
OFCs only.
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The present study was designed to test maternal GDM and hypertension
hypotheses in relation to OFCs. High quality data were available on several
conceptually relevant covariates to control for potential confounding. Statistical
analyses were conducted for isolated, multiple, and isolated and multiple cleft groups
combined and cleft subtypes (CPO, CL/P, and all clefts). The effects of maternal
GDM and hypertension and maternal BMI categories on the risk of OFC were all
evaluated. Although DM has been reported by previous studies to be correlated with
the risk of congenital birth defects 23, 24, and some reported to have an effect on
increasing the risk of OFC 25, 26, studies of the association between maternal GDM
and OFC are limited. Similarly, studies of the association between maternal
hypertension and OFC are limited.
We also conducted a pooled analysis using individual data on GDM and
hypertension and potential confounding factors (age, smoking three months prior to
pregnancy, multivitamin use, education level, and BMI categories). The risk of
orofacial clefting by maternal GDM and hypertension by maternal BMI categories
was also evaluated.
The presence of GDM and hypertension were determined based on maternal
self-reports of diagnosed GDM that were similar to approaches used in previous
population-based case-control studies of birth defects 27, 28. Hypertension status was
also determined based on self-reports. Self-reported GDM may lead to
misclassification as some women who reported having no DM may have had
undiagnosed type-2 DM. However, there is no reason to believe that the subsequent
misclassification of GDM status occurred differently for case and control mothers in
this study, so the net effect was probably of an attenuation of associations of diabetes
mellitus with OFC birth defects.
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Other potential limitations of this study include the use of self-reported pregestational weight and height and the possibility of recall bias for these variables.
Data on exposures to smoking, and multivitamin intake were limited to dichotomous
exposure levels, thus residual confounding related to these factors is a possibility. As
in all case-control studies, recall bias is a concern.
In the present study, a positive association was found between maternal GDM
and OFCs in the offspring. Navarrete et al. indicated a definitive relation between a
maternal glucose metabolic disorder and congenital malformations 12. Several other
studies reported an increased risk for having newborns with OFCs in diabetic mothers
compared to non-diabetic mothers 26, 29-31. Although GDM has been also reported by
previous studies to increase the risk for congenital birth defects 27, 32, 33, including
OFC 2, studies of the association between GDM and OFC are limited. In our study,
we found a significant positive association between GDM and isolated, non-isolated,
and all clefts.
Hypertension has been reported to be associated with congenital
malformations 4, while Lebby et al. indicated no effect of the presence or absence of
hypertension on OFC risk 5. In fact, there is a lack of published studies examining the
association between maternal hypertension and the risk of OFC. In the present study,
we found an increased risk of non-isolated and all CPO, CL/P, all clefts. It is possible
that hypertension during pregnancy alters the perfusion in the placenta, causing
urogenital malformations. However, the exact teratogenic effect of hypertension is
still unknown 34.
A case-control study reported an increased risk of isolated and multiple birth
defects by maternal GDM in the presence of maternal obesity after adjusting for
maternal BMI, age, race/ethnicity, entry into prenatal care, study center, and
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household income (aOR=1.42 [95% CI 1.17-1.73] and 1.50 [95% CI 1.13-2.00],
respectively) 2. Similarly, our results show a higher risk of GDM for isolated
(aOR=4.473 [95% CI 1.13-17.76]), non-isolated (aOR=16.35 [95% CI 2.71-98.62]),
and all clefts (aOR=6.07 [95% CI 1.64-22.47]) among obese mothers, while maternal
hypertension increased the risk for non-isolated OFC only among obese mothers
(aOR=22.21 [95% CI 2.22-334.23]).
While maternal GDM appears to be associated with cleft risk, pregnant
mothers are not usually tested for hyperglycemia until 26-28 weeks of gestation, after
formation of the lip and palate. Thus, we highlight the importance of early screening
of all pregnant women for hyperglycemia at the time of conception. This may
alleviate the risk of GDM and reduce the prevalence of OFC associated with GDM.
Maternal hypertension is associated with the risk of OFC. However, studies are
limited. Further research on the relationship between maternal hypertension, GDM
and DM, and other metabolic syndrome factors might be warranted.
Our findings expand on the body of literature of OFC among infants of
women with GDM or hypertension. Given that both maternal GDM and hypertension
were associated with an increased risk of OFCs, both CL/P and CPO, the importance
of identifying and implementing effective detection, control, and prevention strategies
for metabolic abnormalities, including maternal GDM and hypertension, among
women of childbearing age is a necessity.
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CHAPTER 5
THE ASSOCIATION BETWEEN MATERNAL DIABETES AND OROFACIAL
CLEFTS IN AN INTERNATIONAL CONSORTIUM OF
CASE-CONTROL STUDIES1
Abstract
Objective: To evaluate whether maternal diabetes mellitus (DM) is independently
associated with risk of orofacial clefts (OFCs).
Methods: Pooled analyses of population-based case–control studies from a unique
and large international consortium including Utah, Iowa, Norway (two studies 19962001 and 2000-2009, Denmark, and the U.S. National Birth Defects Prevention Study
was conducted. Subjects included mothers of 5,280 infants with OFCs and 11,461
controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to
estimate the relative risk for cleft subtypes associated with diabetes. Multiple logistic
regression analysis was used to adjust for the potential confounding effects of
maternal age, multivitamin use, maternal body-mass-index (BMI) categories, and
history of smoking.
Results: Maternal DM was associated with an increased risk of all types of OFCs
after adjustment for maternal age, multivitamin use, smoking during the first trimester
of pregnancy, and BMI. The estimated relative risk of DM for isolated OFCs was 1.33
[95% CI 1.14-1.54] and was slightly higher for multiple OFCs (aOR=1.86 [95% CI
1.44-2.40]). No excess risk was observed among diabetic mothers with normal body
weight. However, diabetic mothers who were also overweight or obese had an
increased risk for having children with isolated, multiple, and isolated and multiple

1
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OFC groups combined (aOR=1.33 [95% CI 1.02-1.73], 2.61 [95% CI 1.71-3.97], and
1.52 [95% CI 1.19-1.93]), respectively. We also found an elevated risk of OFCs
among mothers with diabetes who were underweight (aOR=2.63 [95% CI 1.26-5.49].
Conclusions: Maternal DM was significantly associated with an elevated risk of all
types of OFCs. Mothers of normal bodyweight however had no increased risk of
OFCs if they were diabetic; the elevated risk among diabetics only occurred among
underweight, overweight, and obese mothers. Further studies are needed to identify
diabetes related pathways leading to the increased risk of OFCs and to understand
how this risk is modified by risk factors related to both underweight and overweight.
Our findings also highlight the need to assess all mothers for hyperglycemia and other
metabolic abnormalities in the periconceptional period to reduce the risk of OFC in
their offspring.
Introduction
Maternal diabetes mellitus (DM) has been implicated in several studies as a
possible etiological factor of various infant congenital malformations 1-3. Orofacial
clefts (OFCs) are among the most frequent congenital birth defects 4. In 2006, Centers
for Disease Control and Prevention (CDC) reported that from 1999 through 2001,
nearly 4,209 infants each year in the United States are born with OFCs 5. These
estimates have been increased in 2010 to 4,437 live births per year 6. Several studies
suggest that maternal diabetes or the underlying metabolic abnormalities known as the
metabolic syndrome may be involved in the pathogenesis of cleft lip and cleft palate 79

. However, further studies are needed for a more complete understanding of the

etiology of this disorder 10.
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DM is a group of metabolic diseases resulting from defects in insulin
secretion, insulin action, or both, and characterized by chronic hyperglycemia with
disturbances of carbohydrate, fat and protein metabolism. Three main types of
diabetes have been defined: type-1, type-2, and GDM 11. Type-1 diabetes mellitus or
insulin-dependent diabetes mellitus (IDDM) is partly inherited and then triggered by
certain infections. It results from a T-cell mediated autoimmune destruction of the
pancreatic beta cells in genetically predisposed individuals 12. Type-2 diabetes or noninsulin-dependent diabetes mellitus (NIDDM) is due primarily to lifestyle factors and
genetics 13. GDM is a condition in which women without previously undiagnosed
diabetes exhibit high blood glucose levels (particularly during third trimester of
pregnancy) when their bodies do not secrete excess insulin required during pregnancy
14

.
Type-1 and type-2 are both conditions that can be treated but not cured 15.

GDM may increase the risk for developing diabetes when they are not pregnant 16. It
has been predicted that mothers who develop GDM later in pregnancy may also have
had undetected metabolic problems earlier in the pregnancy 17. Hence, diet, exercise,
and use of appropriate medications to keep blood sugar levels as close to normal
"euglycemia" can be achieved 15.
In 1970, Navarrete et al. found an association between congenital
malformation of infants and the development of diabetes in their mothers later in life
and suggested research into the early phases of diabetic state in mothers pregnant of
malformed infants 18. Several studies reported an increased risk for having newborns
with OFCs in diabetic mothers compared to non-diabetic mothers 19-22 with a higher
statistical significant rate of cleft palate only (CPO) 20.
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Thus, investigation of DM may provide useful clues regarding birth defects
associations 23. We assessed the relationship between maternal DM and the risk of
OFC birth defects. DM is hypothesized to cause OFCs via metabolic abnormalities
that affect fetal development. This hypothesis was examined in analyses of data from
the international consortium of case-control studies from Utah, Iowa, Norway,
Denmark, and the U.S. National Birth Defects Prevention Study.
Materials and Methods
This study is a combined, unique, and large international consortium of casecontrol studies from the U.S. (two separate studies from Iowa, Utah, and the U.S.
National Birth Defects and Prevention Study-NBDPS), Denmark, and Norway. The
combined sample includes 16,741 women including 5,280 mothers of children with
OFCs and 11,461 mothers of unaffected children. Data were available on the presence
of DM, pre-pregnancy maternal weight and height, in addition to other perinatal and
demographic factors, which are used as covariates to control for potential
confounding. Body-mass-index (BMI) was computed as weight kilograms
(kgs)/height (m2) and used to define body weight categories as underweight
(BMI<18.5 kg/ m2), normal weight (18.5 <25 kg/ m2), overweight (25 <30 kg/ m2)
and obesity (≥30 kg/ m2). Studies included in this current study are as follows:
(1) Iowa Case-Control Sample: The Iowa Registry of Congenital and Inherited
Disorders (IRCID) case-control sample consists of about 287 cases with CL/P and
302 controls born between 1987 through 1996. The control sample was randomly
selected from all unaffected live births and matched to the affected sample by birth
month, year and gender. Data on risk behaviors, socioeconomic characteristics and
other relevant data, were obtained through telephone-based interviews and self-
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administered forms sent by mail 24.
(2) Utah Study: A state-wide case-control study of clefts was conducted in
Utah during 1995 to 2004 in collaboration with the Utah Birth Defects Network
(UBDN) involves 561 cases with CL/P and 660 randomly selected unaffected births
(from birth certificates) matched cases by month, year of birth, and gender of the
child. The UBDN staff members attempted to contact potential case and control
mothers by mail to obtain consent for release of their names to USU investigators.
Address updates were sought using available Internet services. If no mailing address
was available, attempts were made to locate the mothers in person by field tracing that
included visits to the last known home address and inquiries with neighbors. The
UBDN later joined the National Birth Defects Prevention Study (NBDPS) described
below. A detailed description of data collection is provided elsewhere 25.
(3) National Birth Defects Population Studies: NBDPS samples with CL/P and
control samples multiple participating States were included. These include Arkansas,
California, Georgia, Massachusetts, New Jersey, New York, North Carolina, Iowa,
Texas and Utah. NBDPS sample provided 3491 CL/P cases and 8357 control
mothers, matched by State and birth year to the CL/P sample 26.
(4) Danish Study: The data were extracted from the Danish National Birth
Cohort study between 1997 and 2003 and involved a sample of 828 mothers of
affected cases with CL/P and 156 randomly selected mothers of unaffected births. The
women were typically enrolled in the study at the first visit to general practitioners
(usually in the first trimester). Participated mothers were interviewed about a broad
range of health related information, such as health and risk behaviors, potential fetal
risk factors, socioeconomic and other relevant characteristics. Further follow-up with
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mothers of children with congenital anomalies was conducted after birth and until the
child is 18 months of age.
(5) Norway Facial Cleft Study: The Norway Facial Clefts Study, or Norway
Case-Control study (Norway CC), is a population survey of infants born with CL/P in
Norway in 1996 through 2001. Data included 570 cases and their parents and a
randomly selected control sample of 736 infants born without birth defects in the
same period 27. Extensive data on maternal behaviors and household factors and
socioeconomics were available. The data collection is described elsewhere 28.
(6) Norway National Mother and Child Cohort Study: The Norwegian Mother and
Child Cohort Study (MoBa), conducted by the Norwegian Institute of Public Health
(NIPH, Oslo, Norway), is a cohort consisting of pregnancies recruited beginning in
1999 to 2008 29. Identified were 164 cases of CL/P and 551 control mother of which
were randomly selected with matching to the case sample by year and state of birth.
Data on maternal health behaviors, demographic and socioeconomic characteristics,
health problems and food behaviors were obtained during pregnancy between weeks
15 and 30 (data on risk and health behaviors was collected between 15 and 18 weeks).
The study also involved follow-up interviews with the mother and child until the child
is three years.
SPSS statistical analysis version 20.0 was used to describe the characteristics
of study population. Descriptive analysis was conducted in SPSS to examine the
association between maternal DM and other factors, such as maternal age, history of
smoking (three months prior to conception), multivitamin use during the
periconceptional period, and education level (college graduate, high school graduate
only, and less than high school graduate) and alcohol consumption.
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Simple Chi-square analysis of contingency tables for categorical analysis was
used to examine the association between each independent variable and selected
covariates, such as maternal educational level, multivitamin use during the first
trimester of pregnancy, smoking, and alcohol consumption.
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to
estimate the relative risk for cleft lip only (CLO), cleft lip with or without cleft palate
(CL/P), cleft lip and cleft palate (CLP), cleft palate only (CPO), and all orofacial
clefts (OFCs) according to the presence of diabetes. Multiple logistic regression
analysis was used to adjust for differences in maternal age, multivitamin use, maternal
BMI categories, and history of smoking, and model the effect of diabetes on OFC
risk.
Results
Table 5-1 summarizes the types of clefts, the numbers, and the sources of
samples. Among the case children, CL accounted for 23.09% (n=1,219), CL/P
accounted for 65.36% (n=3,451), and CP accounted for 34.68% (n=1,831) of cases.
Within CL cases, 1,107 (90.8%) and 112 (9.2%) children cases were reported to have
isolated and multiple birth defects, respectively. Isolated CL/P accounted for 2,976
(86.2%) cases and 475 (13.8%) cases had multiple CL/P. Within CP cases, 1345
(73.5%) and 486 (26.5%) CP cases had isolated and multiples, respectively (table 52).
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Table 5-1. Number of Controls and Orofacial Cleft Cases by Cleft Type and Study
Site
Number of study participants by cleft type
Site and Birth years

Iowa, USA
(1987-1991)
Utah, USA
(1995-2004)
U.S. National Birth Defects Prevention Study
(1997-2008)
Danish National Birth Cohort
(1998-2001)
Norway Case-Control Study
(1996-2001)
Norway Mother-Baby (MoBa) Study
(2000-2009)
Total sample

Controls

CLO

CPL

CPO

All OFCs

302

56

111

120

287

660

142

232

187

561

8357

792

1491

1208

3491

828

58

72

57

187

763

140

234

196

570

551

31

94

63

184

11461

1219

2234

1831

5280

Table 5-2. Number of Orofacial Cleft Cases by Cleft Type; International
Consortium of Orofacial Cleft Case-Control Study
Cleft Type

Cleft Lip Only

Cleft Lip with or

Cleft Palate Only

without Cleft Palate
Isolated Clefts

1107

2976

1345

Multiple Clefts

112

475

486

All Clefts

1219

3451

1831

Demographic characteristics of the sample appear in table 5-3. The mean ages
of mothers of cases and controls were significantly different at Iowa (p-value=0.002)
and NBDPS (p-value<0.001) study sites. Smoking during the first trimester of
pregnancy was common and associated significantly with the risk of OFCs among
Utah (p-value=0.002), Danish (p-value=0.035), Norway (p-value<0.01) and NBDPS
studies (p-value<0.05). Maternal BMIs of mothers of cases and controls were
significantly different among NBDPS sample group, but not at other study sites. Use
of alcohol by the mother during the first trimester of pregnancy was significantly
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more frequent (p-value=0.004) among the case versus control mothers in Norway
study; no significant associations were seen in the other studies. Maternal caffeine use
during the first trimester was associated significantly with the risk of OFCs in MoBa
study only (p-value=0.023). Maternal employment was significantly associated with
the risk of OFC among Norway sample (p-value=0.019) and NBDPS sample (pvalue=0.018), but was not among any other study sites. Maternal multivitamin (MVI)
use was significantly associated with the risk of OFC within NBDPS (p-value=0.024)
sample only. Maternal education was associated with the risk of OFC within Norway
sample (p-value=0.040) and NBDPS samples (p-value <0.001).
The prevalence of DM was 5.3% among control mothers and 7.2% among
case mothers. The prevalence of DM varied considerably across study sites and
generally higher in the U.S. sites compared to the European sites. In subgroup
analyses, maternal DM was significantly associated with the risk of OFCs in the Utah
and NBDPS samples, where higher percent of cases among diabetic mothers were
observed (5.7% and 9.3%) compared to controls (2.6% and 6.6%), respectively.
Maternal age of mothers of cases and controls were significantly different among
Iowa (p-value=0.004) and NBDPS (p-value<0.001) study sites. Maternal smoking
during the first 3 months of pregnancy differed between case and control mothers in
Utah (p-value=0.006), Norway (p-value=0.016), and Iowa (p-value=0.026). Maternal
BMIs of mothers of cases and controls were significantly different among Utah (pvalue<0.001), Norway (p-value=0.021), and NBDPS (p-value<0.001). Maternal
alcohol and caffeine use were not significantly associated with maternal DM of cases
and controls at any study site. Maternal education level was significantly associated
with maternal DM in NBDPS sample, but not at other study sites.
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Table 5-3. Demographic Characteristics of Mothers of Children with Orofacial Cleft Cases and Controls by Study Sites
Study Site
Characteristics

Utah

Norway CC

Moba

Iowa CC

Danish

NBDPS

Cases

Controls

Cases

Controls Cases

Controls Cases

Controls

Cases

Controls

Cases

Controls

Maternal age in years + standard
deviation (SD)

27.0
+5.7

26.8
+5.2

28.9
+5.0

29.2
+4.8

29.9
+5.0

30.0
+4.6

26.7
+5.3

27.1
+4.9

26.9
+6.2

26.9
+6.1

29.5
+4.5

30.0+
4.12

Mean maternal body mass
index (BMI; kg/M2) + SD

24.3
+5.0

24.2
+5.3

23.7
+4.4

23.4
+3.7

23.9
+4.2

24.0
+4.2

23.5
+5.2

23.0
+4.4

25.3
+6.2

25.0
+5.8

24.3
+4.6

23.6
+4.2

Smoker %

13.5

8

41.6

31.8

27.6

23.8

25.1

22.2

21.2

16.2

6.2

21.9

Alcohol use in 1st trimester %

7.5

6.4

38.1

30.5

12.7

14

34.5

34.8

22.9

22.5

43.3

42.6

Maternal employment %
Maternal caffeine use in first
Trimester %
Multivitamin use %

88.1

85.6

80.2

85.1

78.6

79.2

N/A

N/A

69.5

71.7

NA

NA

98.6

98.3

89.6

89.8

86.2

92.4

85.0

83.8

70.9

69.8

95

92.4

75.8

75.6

37.2

40.6

70.7

74.6

63.6

71.1

82.2

83.9

56.2

61.3

Education < High school %

8.0

6.5

16.1

11.4

5.7

2.6

9.8

7.6

19.9

17.3

N/A

N/A

College Graduate %
High School graduate %

26.7
65.2

30.5
63

39.6
44.2

40.9
47.7

62.7
31.6

62.4
34.9

18.1
72.1

22.5
69.9

26
54.2

31.6
51.1

N/A
N/A

N/A
N/A

Male %

59.2

60.6

60.3

53.3

58.2

55.2

53.8

54

58.6

50.9

N/A

N/A

Diabetes (%)

32 (5.7)

17 (2.6)

2 (0.4)

4 (0.5)

1 (0.5)

7 (1.3)

21 (7.3)

15 (5.0)

325 (9.3)

555 (6.6)

0(0.0)

5 (0.6)
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Because crude and adjusted ORs (aOR) were very similar, only aORs are
presented. The estimated relative risk for having offspring with isolated clefts,
multiple clefts, and all clefts increased significantly with maternal DM (aOR=1.33 [CI
95% 1.14-1.55], aOR=1.86 [CI 95% 1.44-2.40], and aOR=1.41 [CI 95% 1.23-1.62]),
respectively (table 5-4). Maternal DM was associated with significantly increased risk
for having CL, CL/P, and CP among the isolated OFC, with aORs ranging from 1.29
to 1.39; among multiple CL/P and CPO, with aORs of 1.74 [CI 95% 1.22-2.49] and
2.00 [CI 95% 1.42-2.82] respectively, and among isolated and multiple cleft groups
combined, with aORs ranging from 1.35 to 1.52.
Table 5-4. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals
(CIs) of Orofacial Cleft Types and Subtypes by Maternal DM
Cleft Types

Cleft Lip Only

Isolated Clefts

1.37 [1.06-1.79]

Multiple Clefts
Isolated and nonisolated Clefts
Combined
1 Covariates

Cleft Lip with or
without Cleft
Palate

Cleft Palate Only

All Clefts

1.29 [1.09-1.55]

1.40 [1.11-1.75]

1.33 [1.14-1.55]

1.08 [0.43-2.70]

1.74 [1.22-2.49]

2.00 [1.42-2.82]

1.86 [1.44-2.40]

1.35 [1.05-1.74]

1.35 [1.15-1.60]

1.53 [1.25-1.86]

1.41 [1.23-1.62]

in logistic regression models include study site, maternal age, education levels,
multivitamin use, maternal BMI categories, and history of smoking
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Statistical analyses were used to evaluate the possibility of effect modification
of the association between maternal DM and OFCs by maternal weight categories
(table 5-5). In a multiple logistic regression analysis that controlled for maternal age
groups, maternal smoking during the first trimester of pregnancy, multivitamin use,
and education (college graduate vs. not college graduate) shown in table 9, the
estimated relative risk for having isolated and all clefts increased significantly with
maternal underweight (1.0 [reference]; OR= 2.76 [95% CI 1.29-5.93] and 2.63 [95%
CI 1.26-5.49]), respectively. Maternal overweight and obesity increased the risk of
having isolated, multiple, and isolated and multiple clefts combined significantly,
with aOR ranging from 1.33 to 2.61. DM was not associated with OFCs among
normal weight mothers.
Table 5-5. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals
(CIs) of Orofacial Cleft Types by Maternal Diabetes Stratified by Maternal Body
Weight Categories
Maternal
Body Mass Index
(BMI) Group
Underweight
BMI <18.5
Normal weight
BMI >18.5, < 25
Overweight
BMI >25, <30

Isolated Clefts
n=4319

1.45 [1.10-1.91]

1.81 [1.13-2.91]

1.51 [1.17-1.96]

Obese
BMI >30

1.33 [1.02-1.73]

2.61 [1.71-3.97]

1.52 [1.19-1.93]

1 Covariates

Non-isolated Clefts
n=961

All Clefts
n=5280

2.76 [1.29-5.93]

2.13 [0.56-8.05]

2.63 [1.26-5.49]

1.11 [0.85-1.44]

1.13 [0.67-1.92]

1.11 [0.87-1.43]

in logistic regression models include study site, maternal age, education levels,
multivitamin use, and history of smoking.
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The estimated relative risk of DM with maternal underweight for having
isolated and all CPO (OR=4.26 [1.58-11.48] and 4.00 [1.59-10.04]) respectively
appeared to be higher than in the other body weight groups. Maternal overweight
increased the risk for isolated, multiple, and all CL/P in addition to isolated and all
CPO. Maternal obesity increased the risk for isolated and all CLO; isolated, multiple,
and all CL/P; and multiple and all CPO. Diabetic normal weight mothers had no
increased risk for any OFC type (table 5-6).
Table 5-7 shows the aORs of OFCs types and subtypes by maternal DM
stratified by maternal periconceptional multivitamin (MVI) use vs. non-multivitamin
use. The results demonstrate a slightly decreased risk of isolated (aOR=1.30 [95% CI
1.01-1.54]) and isolated and non-isolated OFC groups combined (aOR=1.35 [95% CI
1.15-1.57]) among MVI users compared to non-MVI users (aORs=1.48 [95% CI
1.05-2.09] and 1.72 [95% CI 1.26-2.35], respectively). However, the effect of MVI
use in attenuating the risk of OFCs among mothers with DM appeared to be stronger
for OFCs with multiple birth defects (aOR=1.62 [95% CI 1.19-2.20]) compared to
non-multivitamin users (aOR=2.73 [95% CI 1.67-4.46]).
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Table 5-6. Adjusted Odds Ratios (aORs)1 and 95 Percent Confidence Intervals (CIs) of Orofacial Cleft Types and Subtypes
by Maternal Diabetes Stratified by Maternal Body Weight Categories
Orofacial Cleft
Type

Isolated
Clefts

Multiple
Clefts

Isolated and
Multiple Clefts
Combined

1 Covariates

Maternal Body
Weight Category

Cleft Lip Only

Cleft Lip with or
without Cleft Palate

Cleft Palate Only

All Clefts

Underweight
BMI <18.5
Normal Weight
BMI>18.5, <25
Overweight
BMI>25, <30
Obesity
BMI >30
Underweight
BMI <18.5
Normal Weight
BMI>18.5, <25
Overweight
BMI>25, <30
Obesity
BMI >30
Underweight
BMI <18.5
Normal Weight
BMI>18.5, <25
Overweight
BMI>25, <30
Obesity
BMI >30

2.01 [0.53-7.55]

2.16 [0.89-5.20]

4.26 [1.58-11.48]

2.76 [1.29-5.93]

0.92 [0.55-1.52]

1.01 [0.74-1.39]

1.29 [0.87-1.91]

1.105 [0.85-1.44]

1.58 [0.99-2.53]

1.39 [1.00-1.92]

1.53 [1.01-2.32]

1.45 [1.10-1.91]

1.68 [1.07-2.65]

1.43 [1.06-1.94]

1.15 [0.75-1.75]

1.33 [1.02-1.73]

4.56 [0.47-44.33]

1.34 [0.17-10.81]

3.35 [0.66-16.86]

2.13 [0.56-8.05]

0.61 [0.08-4.44]

0.98 [0.45-2.12]

1.27 [0.64-2.53]

1.13 [0.67-1.92]

0.85 [0.11-6.48]

2.09 [1.10-3.96]

1.60 [0.82-3.09]

1.81 [1.13-2.91]

1.27 [0.28-5.86]

2.19 [1.23-3.91]

3.21 [1.81-5.69]

2.61 [1.71-3.97]

2.37 [0.73-7.71]

2.02 [0.86-4.74]

4.00 [1.59-10.04]

2.63 [1.26-5.49]

0.89 [0.54-1.46]

1.01 [0.75-1.37]

1.29 [0.91-1.83]

1.11 [0.865-1.43]

1.53 [0.96-2.41]

1.47 [1.09-1.99]

1.54 [1.07-2.22]

1.51 [1.17-1.96]

1.64 [1.06-2.55]

1.53 [1.15-2.02]

1.53 [1.08-2.17]

1.52 [1.19-1.93]

in logistic regression models include study site, maternal age, education levels, multivitamin use, and history of smoking.
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Table 5-7. Adjusted Odds Ratios (aORs) and 95% Confidence Intervals (CIs) of Orofacial Cleft Types and Subtypes by Maternal
Diabetes Stratified by Maternal Multivitamin (MVI) Use
Status of
Multivitamin
Use
MVI Users

Non-MVI Users

1 Covariates

Orofacial Cleft Type

Cleft Lip Only

Cleft Lip with or without
Cleft Palate

Cleft Palate Only

All Clefts

Isolated Clefts

1.27 [0.94-1.72]

1.24 [1.02-1.51]

1.41 [1.10-1.82]

1.30 [1.10-1.54]

Multiple Clefts
Isolated and Multiple
Clefts Combined
Isolated Clefts

0.85 [0.26-2.75]

1.35 [0.86-2.13]

1.91 [1.28-2.83]

1.62 [1.19-2.20]

1.24 [0.92-1.67]

1.25 [1.04-1.51]

1.41 [1.10-1.82]

1.34 [1.15-1.57]

1.89 [1.10-3.26]

1.57 [1.07-2.31]

1.30 [0.76-2.22]

1.48 [1.05-2.09]

Multiple Clefts
Isolated and Multiple
Clefts Combined

1.83 [0.41-8.10]

3.20 [1.72-5.94]

2.19 [1.08-4.45]

2.73 [1.67-4.46]

1.87 [1.11-3.15]

1.83 [1.29-2.59]

1.30 [0.76-2.22]

1.72 [1.26-2.35]

in logistic regression models include study site, maternal age, maternal BMI categories, education levels, and history of smoking.
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Discussion
This study provides evidence that maternal DM significantly increases the risk
of having a child with OFC. An association between maternal DM among obese
mothers and increased risk of isolated, multiple, and isolated and multiple clefts
combined found to be statistically significant. Interestingly, the risk of maternal DM
among underweight mothers appeared to be higher than among obese mothers in
isolated and isolated and multiple cleft groups combined, while no excess risk was
found among diabetic mothers with normal weight.
This is the largest international consortium of case-control study to date with
multiple countrywide sites in Europe and statewide sites in the US. The study is
population-based and relatively robust against selection bias. OFC cases were drawn
from birth defects registries. Data on potential confounders were obtained through the
process of interviewing participants. The study was designed to use well-defined
procedures for case definition and careful classification of OFCs and associated
conditions by clinical specialists.
The present study was designed to test the maternal DM hypothesis in relation
to OFCs. High-quality data were available on several conceptually relevant
covariates to control for potential confounding. Statistical analyses were conducted
for isolated, multiple, and isolated and multiple cleft groups combined and cleft
subtypes. The effects of maternal DM and maternal BMI categories on the risk of
OFC were all evaluated. As DM is an epidemic health problem, a modest effect of
maternal DM can be linked to a significant burden of OFCs. We also conducted a
pooled analysis using individual data on DM and potential confounding factors (age,
smoking during the first trimester of pregnancy, multivitamin use, education level,
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and BMI categories). The risk of orofacial clefting by maternal DM by maternal BMI
categories was also evaluated.
The presence of DM was determined based on maternal self-reports of
diagnosed DM that were similar to approaches used in previous population-based
case-control studies of birth defects 30, 31. This is subject to DM status
misclassification as some women who reported having no DM may have had
undiagnosed type-2 DM. However, there is no reason to believe that the subsequent
misclassification of DM status occurred differently for case and control mothers in
this study, so the net effect was probably of an attenuation of associations of diabetes
mellitus with OFC birth defects.
Other potential limitations of this study include the use of self-reported pregestational weight and height and the possibility of recall bias for these variables.
Data on exposures to smoking, and multivitamin intake were limited to dichotomous
exposure levels, thus residual confounding related to these factors is a possibility. As
in all case-control studies, recall bias is a concern.
With the rising rates of DM 32, the current findings of the association between
maternal DM and OFCs in the offspring is a major public health concern. Studies of
the association between maternal DM and risk of OFCs have produced somewhat
consistent findings for the positive effect of DM, although an inconsistency related to
the effect on the type of cleft has been observed 19, 20, 22, 33, 34. This may be related to
variations in population sample size, definitions of OFC subtypes, lack of
consideration of maternal underweight, and inadequate control of potential
confounding factors.
In the present study, a positive association was found between maternal DM
and OFCs in the offspring. This is similar to results reported by previous studies 19, 20,
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22, 33, 34

. However, Carinci et al., and Arteaga et al. reported a higher correlation

between DM and isolated clefts 20, 34, while Tantbirojnet al. indicated a higher risk of
CL/P among diabetic mothers . Our results indiated an increased risk for isolated,
non-isolated, and both cleft groups combined when maternal DM is present, with a
higher aOR for multiple clefts than in isolated clefts (aOR=1.86 [95%CI 1.44-2.40]
and 1.33 [95%CI 1.14-1.55]), respectively. Yet, the aOR of isolated and non-isolated
cleft groups combined was the highest compared to each separate group (aOR=1.41
[95%CI 1.23-1.62]). This result is consistent with the one reported by Correa et al. in
which the association between maternal DM and multiple defects is stronger than
with isolated defects 2. Possible explanation for the stronger associations with
multiple OFC includes an increased underlying susceptibility and/or exposure to a
more adverse metabolic environment in utero. Further research is warranted to
elucidate the basis for the variation in the ORs by OFC subtype and to identify the
reasons for the stronger associations of DM with multiple defects.
DM has been found in earlier studies to be associated with various birth
defects including OFCs. The consistent finding of the associations between maternal
DM and birth defects suggest the hypothesis that complex underlying metabolic
disorders that are associated with DM increase the likelyhood that signal transduction
pathways and morphogenic processes might be distrubed 35-37.
The association of DM in the presence of obesity with OFC has been observed
in a few other studies 8, 22, 38. Similarly, our results indicate that pregnancies of women
who were both obese and diabetic increase the risk for having an offspring with OFC,
with ORs ranging from 1.33 to 2.61 for isolated, multiple, and both groups combined.
However, pregnancies of women who were underweight and diabetic also appeared to
have a higher risk for OFC compared to obese mothers, with an estimated relative risk
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of 2.8 [95% CI 1.29-5.93] for having offspring with isolated cleft, 2.6 [95% CI 1.265.49] for any type of cleft, and 4.3 fold increased risk [95% CI 1.58-11.48] for
isolated CPO. Rao, 1984 reported an association between maternal undernutrition and
DM. Maternal underweight is a form of undernutrition and can be an important
determinant of DM in an individual through a process of impairing beta cells
progressively or by increasing the susceptibility of the individual to other genetic and
environmental diabetogenic influence 39. Thus, mothers characterized by being lean
can be at a similar risk for developing DM as obese individuals. However, mothers
who are both lean and diabetic may be at an even higher risk to have an infant with
OFC compared to obese mothers.
Multiple CPO represented the highest risk when maternal DM is present
(aOR= 1.98 [95% CI 1.40-2.80]). Maternal obesity combined with DM was also
associated with a higher risk for CPO. On the other hand, women with DM and
normal weight had no excess risk of having offspring affected by OFC. This is similar
to the study reported by Moore et al. 8, suggesting that obesity and DM may act
synergistically in the pathogenesis of congenital abnormalities. Maternal obesity on
cleft palate malformation was reported to have an indirect influence of excess
adiposity due to bioaccumulation and release of dioxins, which have been shown to
cause cleft palate in mice 40. Both obesity and DM are indicators for metabolic
syndrome and are also associated with conditions known as “diabesity” 32, implying a
possible role of metabolic syndrome on palate formation in the embryo 41.
What mechanisms could link maternal DM to OFCs in the offspring?
Whatever the underlying mechanism behind the observed associations is, maternal
DM appears to be associated with the risk of all types of OFC. While no excess risk
of OFCs within diabetic normal weight mothers was found, mothers who were
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diabetic and underweight, overweight, or obese had an increased risk for having
inborn with any type of OFCs. Diabetic underweight mothers showed a higher risk
than that of obese diabetic mothers to have a child with OFC. Thus, maternal DM
combined with obesity or underweight appear to be an indirect measure of cleft risk,
suggesting that the state of mothers being underweight does not reduce or protect
against the risk of OFC. Further studies are needed to understand how this risk is
modified by risk factors related to both underweight and overweight.
DM can be caused by various environmental and genetic factors, including
obesity, sedentary lifestyles, and overnutrition 32. Previous studies reported that even
in the absence of maternal diabetes, obese women have been found to have an
impaired glucose metabolism 42, which may be associated with an elevated risk for
OFCs 8, 19, 22. Multivitamin use appeared to attenuate the risk of OFCs due to DM.
Although OFC deformities occur within the first trimester of pregnancy, and given
that DM is associated with an increased risk for OFC, there is only a few data on
screening tests before 24 weeks' gestation. Therefore, further studies on appropriate
methods for diabetes testing in the periconceptional period for all mothers, including
underweight mothers, are recommended.
This is the largest study to date to test the association between maternal DM
and risk of having a newborn with an OFC. Maternal type-1 DM is significantly
associated with the risk of OFCs. Diabetic women who are also obese have a higher
risk to have an offspring with OFC compared to diabetic mothers with normal weight.
Underweight mothers who are also diabetic have a doubled increased risk to have
inborn with OFC. Multivitamin use appeared to attenuate the risk of OFCs due to
GDM. To prevent this devastating craniofacial anomaly, our findings highlight the
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need of obstetricians and gynecologists to assess all mothers for hyperglycemia in the
periconceptional period to reduce the risk of OFC in their offspring.
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CHAPTER 6
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS
Summary
The overall objective of this dissertation was to determine whether maternal
obesity, diabetes and gestational diabetes, and maternal hypertension are
independently associated with the risk of orofacial cleft (OFC) birth defects. OFCs are
among the most common structural birth defects and a public health problem. There is
a strong evidence of an etiologic role for both genetic and environmental factors.
Environmental factors that have been associated with the risk of cleft include
maternal smoking, multivitamin use, alcohol drinking, socioeconomic status, and
body weight. Several studies suggest that maternal obesity, diabetes mellitus (DM), or
the underlying metabolic abnormalities known as the metabolic syndrome, may be
involved in the pathogenesis of cleft lip and cleft palate, and it is unclear whether this
is true also for maternal gestational diabetes mellitus (GDM). With the rising rates of
excess weight among pregnant women, even a modest effect of maternal obesity may
result in excess risk of OFC. Maternal weight gain increases the risk for DM and
hypertension. Although hypertension has been associated in a few studies with
congenital birth defects, studies examining the risk associated with OFC are limited.
Investigation of metabolic syndrome, with the presence of obesity, diabetes,
hypertension, and other more serious physiologic consequences, may provide useful
clues regarding birth defects associations.
The results of the studies conducted in this dissertation support the roles of
abnormal maternal weight- both underweight and obesity- and gestational diabetes
and hypertension on increasing the risk of OFC. A pooled analysis of populationbased case–control studies conducted using the international consortium of case-
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control studies from Utah, Iowa, Norway, and the U.S. National Birth Defects
Prevention Study confirmed the independent association between maternal obesity
and underweight and the risk of cleft palate. The effect of maternal education level on
the risk of OFC was also tested. Interestingly, an increased risk for cleft lip with
palate, cleft palate only, cleft palate with or without cleft lip, and all clefts was
observed among mothers with lower education levels, while no effect on cleft lip only
was seen. This may suggest a possible indirect effect of maternal education level on
cleft palate risk. Thus, maternal body weight categories association with the risk of all
cleft palate was tested after stratifying by maternal education level. The results
showed an increased risk for cleft palate with or without cleft lip in obese and
underweight mothers when mothers were less educated, with a highest risk observed
among the underweight mothers. Such effect can be related to a combination of
maternal underweight with lifestyle with behavioral factors associated with lower
maternal education. In some previous studies, conclusions about the association
between maternal obesity and orofacial clefting were limited by small number of
cases, while this study represented the largest international consortium of case-control
study to date with multiple countrywide sites in Europe and statewide sites in the U.S.
In a statewide case-control study of clefts conducted in Utah in collaboration
with the Utah Birth Defects Network (UBDN), an increased risk for isolated and nonisolated clefts was observed among mothers diagnosed with GDM; while
hypertension increased the risk for non-isolated and the results were suggestive for
isolated clefts. As maternal obesity has been reported to be associated with both
maternal GDM and hypertension, the risk of isolated and non-isolated OFC was tested
within the different maternal body weight groups. Results indicated an increased risk
for isolated and non-isolated clefts when the GDM is present among obese mothers.
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Hypertension appeared to increase the risk for OFCs and this seems more pronounced
for multiple OFCs and obese mothers.
Lastly, the analyses of the international consortium data revealed an
association between DM on the risk of OFCs across all types (isolated, non-isolated,
and all clefts) and subtypes (cleft lip only, cleft lip with or without cleft palate, and
cleft palate only). When data were stratified by maternal body weight categories,
maternal overweight and obesity combined with the presence of DM appeared to
increase the risk of isolated, non-isolated, and all cleft groups combined. Maternal
underweight status with the presence of DM also increased the risk of isolated and all
cleft groups combined and the risk appeared to be stronger compared to that of
obesity and overweight when combined with DM. Notably, diabetic mothers with
normal weight did not have a significant elevated risks for OFCs.
Limitations and Future Directions
The dissertation described here provides evidence of the roles of maternal
obesity, DM, and GDM, and hypertension on OFC risk after adjusting for potential
confounders. There are some limitations that must be discussed and addressed in
future work. One limitation was the self-reported pre-gestational weight and height
collected in the international consortium data. It is common among obese women to
underreport their weights and overestimate their heights 1, resulting in an
underestimation and misclassification of body-mass-index (BMI). However, even
with the possibility of maternal underestimation of BMI, a significant increase in the
risk of having a child with OFC birth defects was observed among the obese mothers
and that effect could be stronger if the prevalence of obesity in the study sample was
have accurately assessed.
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In addition to the limitations of use of self-reported pre-pregnancy weight and
height and the possibility of recall bias, in the study examining the role of maternal
DM on the risk of OFC, the DM was determined based on maternal self-reports of
diagnosed DM. This is subject to DM status misclassification as some women who
reported having no DM may have had undiagnosed DM. However, there is no reason
to believe that the subsequent misclassification of DM status occurred differently for
case and control mothers in this study, so the net effect was probably of an attenuation
of associations of diabetes mellitus with OFC birth defects.
The role of maternal GDM and hypertension was based on Utah OFC study.
Due to the small number of participants with GDM and hypertension, the confidence
intervals were wide. However, the detection for the increased risk even with this small
sample size was suggestive and should encourage further research.
Although the potential confounders in the analyses of studies in this
dissertation were adjusted for, it is possible that residual confounding exists. To better
understand the underlying etiology of OFCs and whether genes and environmental
risk factors play a causal role for OFCs, future studies are needed.
The following recommendations are also offered for related research on OFC:
1. Given that maternal obesity, DM, and hypertension are all risk factors of
metabolic syndrome, and appeared to have strong effects on increasing the
risk of OFC, further studies on the exact pathophysiology of this syndrome
may help in understanding the causal mechanisms for OFCs.
2. Research related to other potential environmental factors and genes and how
they interact with maternal metabolic abnormalities would be of value to help
better understand the etiology of OFCs.
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3. Based on the results of the dissertation, maternal underweight and obesity may
both have severe effects on the offspring. As it is unclear whether the cause is
related to mothers’ weight or other factors related to body composition, further
research on the difference between obese, but metabolically healthy
individuals and lean, but metabolically unhealthy people may justify why
some people present to have higher risk for metabolic disorders than others,
independently of body weight.
Recommendations for Practitioners
The following recommendations are offered for related research on OFC:
1. Based on the results of this dissertation, it is recommended to modify the
guidelines of maternal screening for abnormal glucose tolerance to be
performed in pre-conceptional and early prenatal visits of all women,
highlighting that underweight mothers should be also tested for as they may
have a higher risk for having offspring with congenital anomalies.
2. Given that obesity, DM, and hypertension are modifiable diseases and can be
prevented through the application of healthy behaviors, it is recommended to
inform and educate mothers planning for pregnancy on distinct practices to
remain healthy and avoid pregnancy complications.
Conclusions
In conclusion, this dissertation presents additional insight into the possible
etiologies associated with OFCs. The findings indicate that maternal obesity and
underweight increase the risk of cleft palate in the offspring significantly; the risk
increases further among mothers with lower education levels, while higher maternal
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education levels protect against the effect of maternal underweight and obesity against
the risk of OFCs. Additionally, the results support the hypotheses that maternal GDM
and hypertension are independently associated with the risk of OFCs. Maternal DM
increases the risk of all types (isolated, non-isolated, and all clefts) and subtypes (cleft
lip only, cleft lip with or without cleft palate, and cleft palate only) of OFCs; and the
risk increases further when maternal obesity is present among diabetic mothers.
Normal weight mothers who were diabetic had no increased risk.
The findings demonstrated here can pose an important role for guiding further
studies to identify risk factors associated with OFCs. Additional studies will be
helpful in elucidating the pathophysiology behind these associations with OFCs.
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